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1. ABSTRACT 
Das humane maligne Mesotheliom (HMM) ist eine asbest-assoziierte neoplastische 
Erkrankung, die durch eine hohe Resistenz gegenüber den herkömmlichen 
zytostatischen Therapien gekennzeichnet werden kann. Vor allem in den westlichen 
Industrieländern wird eine Zunahme der Inzidenz verzeichnet, was vermutlich auf den im 
vergangenen Jahrhundert starken Gebrauch von Asbest zurückzuführen ist. Die 
Prognose der Erkrankung ist schlecht mit einer medianen Überlebensrate von 9 bis 12 
Monate ab dem Zeitpunkt der Diagnose. Der Tumor neigt vor allem zu einer lokalen 
Ausbreitung, während eine Fernmetastasierung selten zu beobachten ist. Radiotherapie 
und Chemotherapie als Monotherapie sind weitgehend ineffektiv. Der chirurgischen 
Therapie kommt demnach eine wesentliche Bedeutung bei kurativer Intention zu. 
Aufgrund der häufig weit fortgeschrittenen Erkrankung bei Diagnose ist allerdings die 
Entwicklung neuer systemischer Therapiekonzepte mit erhöhter Wirksamkeit für 
Mesotheliom-patienten von außerordentlicher Bedeutung. 
Innerhalb des karzinogenen Prozesses, nimmt der mTOR (mammalian target of 
rapamycin) Signalweg allgemein eine zentrale Stellung ein. In vielen soliden Tumoren, 
als auch hämatologischen Neoplasien des Menschen ist diese Signalkaskade durch 
verschiedenste molekulare Mechanismen überaktiviert. Dies führt unter anderem zu 
verstärkter Proliferation, erhöhtem Überlebenspotential und Resistenz gegenüber 
Apoptose und somit gegebenen falls zum Versagen der Chemotherapie. Daher stellt die 
Hemmung des mTOR Pathways einen zentralen Angriffspunkt der modernen, gezielten 
Krebstherapie dar. Der ursprüngliche und namensgebende mTOR-Inhibitor Rapamycin,  
ist ein bekanntes Immunsuppressivum mit antineoplastischer Wirkung.  Folglich wurden 
weitere Rapamycin-Derivate entwickelt, darunter Temsirolimus, das bereits erfolgreich  
klinische Anwendung findet und untern anderem das Überleben von Patienten mit 
fortgeschrittenem Nierenzellkarzinom verbessert. Auch zur Behandlung des seltenen 
Mantelzell-Lymphoms wurde Temsirolimus seit kurzem zugelassen. In Bezug auf das  
maligne Mesotheliom, gibt es Hinweise auf eine häufige Hyperaktivierung des mTOR 
Pathways bzw. des „upstream“ gelegenen PI3K (Phosphoinositid-3-Kinasen) 
Signalwegs, der eine bedeutende mTOR-regulierende Funktion beinhaltet. Mögliche 
Ursachen die zu solch einer Hyperaktivierung beitragen könnten, wären zum Beispiel als 
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der Verlust des PI3K negativen Regulators PTEN (Phosphatase and Tensin homolog) 
als auch  Mutationen einiger wichtiger Wachstumsfaktor-Rezeptoren wie IGF1R (Insulin-
like Growth Factor 1 Receptor) oder HGFR (Hepatocyte Growth Factor Receptor). 
In der hier präsentierten Arbeit wurden immunhistochemische Präparate von HMM 
Tumorproben (n=70) hergestellt und auf dessen mTOR-Phosphorylierungsstatus hin 
untersucht. Die Präparate als auch die hier verwendeten HMM-Zellmodelle (n=6), 
zeigten eine signifikante konstitutive mTOR-Aktvierung. Weiteres wurden die HMM 
Zelllinien mittels array comparative genomic hybridization (aCGH) auf genetische 
Aberrationen der wichtigsten in den mTOR Pathway involvierten Akteure, als auch auf 
allgemeine, häufig mit Krebs assoziierte genetische Mutationen untersucht. Als 
Hauptziel dieser Studie galt es zu evaluieren, inwieweit eine Blockade des mTOR 
Pathways mittels Temsirolimus einen vielversprechenden neuen Ansatz in der Therapie 
des malignen Mesothelioms darstellt. Dabei wurde die Substanz sowohl als 
Monotherapie als auch in Kombination mit der bei dieser Erkrankung verwendeten 
Standard-Chemotherapie (Cisplatin und Pemetrexed) angewandt. Temsirolimus 
bewirkte eine maßgebliche Inhibierung mTOR-vermittelnder Signale und zeigte  
zytostatische Wirkung, sowohl in als adhärenten einschichtigen in vitro kultivierten  
HMM-Zelllinien als auch in nicht-adhärenten Sphäroiden. Mesotheliom-Zelllinien die 
über eine intrinsische Cisplatin-Resistenz verfügten, zeigten hierbei das beste 
Ansprechverhalten. Auch durch in vitro Selektion erworbene Cisplatin-Resistenz, hatte 
eine deutliche Sensibilisierung gegenüber Temsirolimus zur Folge. Interessanterweise 
konnte gleichzeitig demonstriert werden, dass im Gegensatz dazu, die zytotoxische 
Wirkung des zweiten Standard-Chemotherapeutikums  Pemetrexed in  Cisplatin 
resistenten Zellen signifikant reduziert ist. Weiteres zeigte die Kombination von 
Temsirolimus und Cisplatin einen deutlich synergistischen Effekt in der Blockierung der 
mTOR „downstream“-Signaltransduktion und verstärkte die Wachstumsinhibition als 
auch die Indizierung von Apoptose in vitro. Schließlich demonstrierte Temsirolimus eine 
hohe antineoplastische Aktivität gegen HMM xenograft SCID-Mausmodelle als 
Einzelsubstanz als auch in Kombination mit Cisplatin. 
Zusammengefasst legen die hier dargelegten Daten nahe, dass die Inhibierung von 
mTOR im humanen malignen Mesotheliom eine vielversprechende neue Strategie im 
Kampf gegen diese äußerst schwerwiegende Krebserkrankung darstellen könnte. 
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Human malignant mesothelioma is an asbestos-related malignancy characterised by 
frequent resistance against chemo- and radiotherapy. Because of the extensive 
asbestos usage in the last century primarily in western industrial countries an increasing 
incidence is prognosticated for the next decades. Generally, HMM shows a very poor 
prognosis with a median survival of nine to twelve month. Primarily the tumor tends to 
expand into the local areas, while metastasis is only rarely observed. Both, radiation 
therapy and chemotherapy are often intrinsically ineffective or result in acquired 
resistance during the course of disease. Consequently, extensive surgery is still of great 
importance in case of therapy with a curative intention. Due to the fact that in the 
majority of cases HMM is diagnosed only in late stage, an improved understanding of 
the complex molecular changes underlying this neoplasia is urgently needed to develop 
new and probably targeted treatment strategies. 
The oncogenic signalling cascade of mTOR (mammalian target of rapamycin) is known 
to occupy a central position within carcinogenesis. In both, solid and hematopoietic 
tumors, this pathway has been reported to be hyper-activated, not only causing 
increased proliferation and survival, but also seems to confer apoptosis-resistance 
consequently leading to chemotherapy failure. For this reason, the inhibition of mTOR is 
suggested to be a central point of application for novel targeted cancer therapy. The 
primary discovered and name given inhibitor of mTOR, rapamycin, is known to exhibit 
immunosuppressive and anti-neoplastic effects. Its derivate temsirolimus, which is also 
already in clinical use, effectively prolongs survival of patients with mantel cell lymphoma 
and advanced renal cell carcinoma. With regard to human malignant mesothelioma, 
there is evidence that mTOR and also its important upstream regulator PI3K 
(phosphoinositid-3-kinase) are frequently hyper-activated. It is suggested, that deletion 
of PTEN, as negative regulator of PI3K, may be responsible for an aberrant mTOR 
signaling. Also mutations of several growth factor receptors such as IGF1R (insulin-like 
growth factor 1 receptor) or HGFR (hepatocyte growth factor receptor) are thought to 
be at least in part responsible for the genesis of an oncogenic mTOR pathway.                            
In this study, HMM tumor specimen (n=70) were analyzed for mTOR phosphorylation 
status using immunohistochemical standard procedure. The tumor samples and also 
investigated HMM cell models (n=6) showed significant constitutively mTOR hyper-
activation. Further, we performed array comparative genomic hybridization (aCGH) 
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analyses of all HMM cell lines to detect both, possible genomic aberrations of key 
players involved in mTOR signaling and generally frequently reported mutations highly 
associated with carcinogenesis. A further main aspect of this study was to clarify 
whether mTOR inhibition by temsirolimus may be a feasible anti-mesothelioma strategy. 
Therefore cell lines were treated with temsirolimus as single agent or in combination 
with components of the standard chemotherapy regimen (cisplatin and pemetrexed). 
Temsirolimus potently blocked mTOR-mediated signals and exerted a cytostatic effect 
against mesothelioma cell lines in vitro cultured both as adherent monolayers and as 
non-adherent spheroids. Mesothelioma cells intrinsically resistant against the standard 
treatment component cisplatin tended to be hypersensitive against temsirolimus. 
Additionally, acquired cisplatin resistance by in vitro selection was accompanied by 
distinct upregulation of sensitivity against the mTOR inhibitor. In contrast, we observed 
that cytotoxic effects of pemetrexed were significantly reduced in cisplatin resistant cell 
models. Furthermore, cisplatin and temsirolimus exerted synergistic inhibition of the 
mTOR downstream signals and enhanced growth-inhibition and/or apoptosis-induction 
in mesothelioma cell lines in vitro. Finally, temsirolimus was highly active against human 
mesothelioma xenograft models in SCID mice both as single agent and in combination 
with cisplatin. 
Taken together, the here presented data suggest mTOR inhibition as promising novel 
therapeutic strategy against malignant pleural mesothelioma. 
 
  
INTRODUCTION 
Epidemiology 
of cancer 
 
 
15
2. INTRODUCTION 
2.1 Epidemiology of cancer 
Every multi-cellular organism’s base of existence underlies a controlled equilibrium 
between cell growth, differentiation and death. Maintaining this balance requires 
specific cellular responses which are processed by complex extra- and intracellular 
signaling pathways. A consistent dysfunction of this routine may results in an 
uncontrolled growth of cells and further in their spreading into diverse tissues which 
describes the main characteristics of the second most common deadly disease in 
industrial countries: Cancer. 
In Austria over 36.000 people [1] develop malignant neoplasms every year and 
approximately every third European will suffer from cancer during his lifetime [2]. 
Although the understanding of tumor development has made significant progress in the 
last decades, cancer remains a key public health concern and an enormous burden on 
society. 
  Figure 1. Breakdown of estimated 12.7 mil l ion new cases, age standardized incidence 
rates and the most commonly diagnosed cancers by different regions of the world, 2008.
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The human organism features a multitude of autonomic mechanisms to secure that 
aberrant cells are stopped in their deviated progress and do not harm the organism.  
Today it has become basic knowledge that changes in the cellular genome are 
responsible for the malfunction of these protective mechanisms and the origin of 
cancer. Basically these mutations can occur spontaneously or due to environmental 
influences such as carcinogenic substances, physical or chemical mutagens and 
certain viruses. In fact, normally more than one somatic mutation is required to trigger 
all changes necessary for a fully developed tumor cell. Thus, a prominent factor 
determining susceptibility to neoplasia is age [3]. Because mutations occur a whole life 
long, age provides the time necessary for the accumulation of events needed for the 
development of cancer. 
Figure 2. Correlat ion between total cancer incidences and age in the UK 
indicat ive for industrial countries. 
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2.2 Principal mechanisms of cancer development 
Specific genes are responsible for the regulation of cell growth and division – the cell 
cycle. Mutations that interfere with the expression of these key players may induce 
cancer. Thus, genes with the property of initiating neoplastic growth are termed proto-
oncogenes and consequently their expression products proto-oncoproteins [4]. 
Generally aberrant genomic changes that alter proto-oncogenes into carcinogenic 
oncogenes can be classified in three main groups: Migration of DNA within the genome 
(translocation), gene amplification and point mutations. Malignant cells often harbor 
broken chromosomes rearranged in an incorrect manner. It is possible that this 
exchange of DNA material, called chromosomal translocation, affects a proto-
oncogene which may be relocated behind an active promoter over stimulating its 
transcription and hence turning it into an active oncogene. The second main type of 
genetic aberrations, gene amplification, prevalently appears during repair of harmful 
DNA double-strand breaks by homologous recombination. Failures during this complex 
repair mechanism or more frequently due to dysfunction of involved mutated enzymes 
may cause the duplication of a proto-oncogene increasing its expression products. The 
third way how a normal gene can become carcinogenic is a spontaneous single 
substitution, deletion or insertion of one or a few base pairs during DNA replication. The 
rate of these point mutations can be strongly increased by diverse mutagens. If this 
Figure 3. Different types of mutat ions leading to proto-oncogene act ivat ion.  
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Figure 4. Three-stage model of 
carcinogenesis. 
damage is not repaired and hits a proto-oncogene, its product may be modified in a 
way that makes the protein more active (gain of function) or more resistant against 
degradation. All these mechanisms can lead to an aberrant stimulation of the cell-cycle 
and consequently to the genesis of malignancies. 
Besides mutations that cause a stimulation of cell growth, also aberrations of control 
genes that are normally involved in cell-cycle inhibition, DNA-repair or cell-adhesion can 
be responsible for the development of neoplasia by a loss of function. These genes are 
called tumor suppressor genes because the code for proteins which normally prevent 
and/or inhibit cells from uncontrolled growth especially through apoptosis. Every 
mutation that decreases their activity generally leads to permitted stimulation of cell 
growth due to the lack of suppressive factors, a major driving force on the path to 
cancer. 
A third, more specialized, class of genes referred to as ‘caretaker’ genes are also often 
linked to diverse malignancies. They normally protect the integrity of the genome and 
are involved in identification or repair of DNA damages and elimination of aberrant cells. 
When caretaker genes are inactivated, cells may acquire additional mutations based on 
the lost control mechanisms.  
The change from a normal cell to a cancer cell 
commonly requires multiple steps, each one 
adding properties that makes cells more likely 
to become malignant. The process of 
malignant transformation is often described by 
a simplified three-stage model [5, 6]: Initiation 
is the first step and involves a change of the 
cells genome due to a mutation of a proto-
oncogene, tumor suppressor- or caretaker 
gene (see above). In this case, intricate repair 
mechanisms may fail to correct the damaged 
DNA and the cell becomes capable of 
avoiding apoptosis. During the next step, 
called promotion, the initiated cell is 
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stimulated to grow and increases proliferation. The basic cause of this reaction are not 
mutagens like in the first step, it is primary the own body who releases growth factors 
and hormones. This so called none-genotoxic agents are particularly frequent in fast 
regenerating tissue like in the intestine, lung, breast and liver. Also during inflammatory 
events a mutated cell can be stimulated to grow by these none-genotoxic agents, e.g. 
wound healing hormones which normally initiate the regeneration of the affected tissue. 
Thus, especially chronic inflammation is frequently associated with cancer 
development. Through growth and proliferation, accumulated mutated cells form a pre-
neoplastic mass which represents a pre-stage of cancer. This so called benign tumor is 
not capable to invade the surrounding tissue by now, although DNA instability 
increases the risk of further mutations with every cell division. New accumulated 
changes in the genome can now lead to the final step termed ‘progression’. In this 
stage, multitude onco- and tumor suppressor genes are affected and after numerous 
divisions the cells lose their tissue identity and dedifferentiate. This modified cell 
structure and further mutations are responsible for the transformation of a benign tumor 
into an invasive neoplasia. The malign cells have now the potential to infiltrate the 
surrounding tissue and to metastasize to other parts of the body using either the 
lymphatic or hematogenic system.  
With regard to the changes in the population of neoplastic cells and their 
microenvironment through selection of an initiated cell in the first stage up to their 
competition of space and resources within the malignant tumor, cancer can be 
described as a disease of clonal evolution within the body [7]. This Darwinian 
mechanism may be a contribution to apoptosis resistance of a mutated cell because 
evolution generally selects for increased proliferation and survival. Further the 
appearance of invasive property can be explained through the presence of selective 
pressure within a neoplasm [8]. Uncontrolled growth and over-consumption of 
resources consequently leads to limited space and nutrients which might be a selective 
force for dispersal.  
Although the three-stage hypothesis illustrates a convincible path to cancer, further 
theories are more and more accepted. A new way of looking at carcinogenesis, but not 
contradicting earlier concepts, is the cancer stem cell hypothesis. It proposes that a 
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heterogenic malignant tumor mass arises originally from a unique transformed stem cell 
or a dedifferentiated somatic cell that recovered stem cell characteristics [9]. This cell 
represents the source of continuous proliferation and self-renewal capability what 
compensates the fact that differentiated cells cannot indefinitely divide because of 
telomere-shortening (Hayflick limit). Cancer stem cells may also be an important factor 
for tumor regression after therapy. While the differentiated part of the tumor degrades, 
the cancer stem cell survives and causes the relapse. Further tumor metastases 
commonly retain heterogeneity, implying that the origin of a spread tumor had the 
capacity to generate multiple cell types which is a typical attribute of a stem cell. 
2.3 Hallmarks of cancer 
Although cancer displays enormous complexity, a relatively simplified view of 
carcinogenesis suggested by D. Hanahan and R. Weinberg [10]  about ten years ago 
has become a well-accepted model. It comprises six capabilities that are shared by 
most and perhaps all types of human tumors: insensitivity to growth-inhibitory signals, 
self-sufficiency in growth signals, evasion of programmed cell death (apoptosis), 
limitless replicative potential, sustained angiogenesis, and tissue invasion and 
metastasis. Recent years have seen that this model should be revised to include a 
probable seventh hallmark: cancer-related inflammation. 
2.3.1 Self-sufficiency in growth signals 
Normal cells require specific stimulatory signals from their tissue microenvironment to 
end their quiescent status and to move into a proliferative state. In contrast tumor cells 
cultured in vitro show a greatly reduced dependence on these exogenous factors 
suggesting that neoplastic cells are capable of generating autocrine growth stimulation 
[10]. Consequently critical mechanisms that are normally in order to ensure the 
homeostasis of various cell types within the tissue are disrupted. In addition to mutated 
oncogenes further factors can be responsible for this attribute. Numerous types of 
cancer feature deregulated growth signal transducing cell surface receptors carrying a 
tyrosine kinase activity which represents an important mechanism in signal transduction 
for regulation of cellular activity. An overexpression of these receptors may enable a 
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cancer cell to become hyper responsive to levels of growth factors that would normally 
be insufficient to trigger proliferation [10]. Further overexpression and/or structural 
alteration of receptors may lead to ligand-independent signaling allowing growth even 
without an appropriate stimulation. 
2.3.2 Insensitivity to growth-inhibitory signals 
The normal tissue is kept in homeostasis by specific signals that inhibits 
growth/proliferation or induce entrance into a postmitotic, differentiated state that is 
usually associated with acquisition of quiescent traits. These signals are received by 
transmembrane cell surface receptors and further coupled to intracellular pathways. An 
aberrant cell has generally two opportunities to evade this circuit: On the one hand the 
deficiency of signal transducing receptors blocks the initiation of growth-inhibitory 
pathways strait from the beginning by lock out of sensed antigrowth factors, a 
characteristic phenomenon of many malignant cells. On the other hand typical 
mutations of tumor suppressor genes consequently lead to the dysfunction of 
intracellular pathways, resulting in the inability of preventing cells from uncontrolled 
growth [10, 11]. 
2.3.3 Evading apoptosis 
If a cell that accumulated mutant onco- and tumor suppressor genes becomes 
aberrant and does not respond to any repair mechanisms, the organism normally starts 
to defend himself by inducing apoptosis. This programmed cell death is a series of 
biochemical events that lead to disruption of cellular membranes, break down of 
cytoplasmic and nuclear skeletons, chromosomal degradation and fragmentation of the 
nucleus within a very short period. Finally phagocytes start to engulf the remaining cell 
parts (apoptotic bodies) until their complete disappearance [12]. For this reason an 
aberrant cell primarily has to circumvent this major barrier to cancer. This becomes 
possible if the accurate cohort of particularly pro-apoptotic genes is affected by 
irreversible mutations or anti-apoptotic proteins are overexpressed [10]. 
INTRODUCTION 
Hallmarks 
of cancer 
 
 
22
2.3.4 Limitless replicative potential 
All previously mentioned acquired capabilities may be the beginning path to cancer but 
are still not sufficient to enable the generation of expansive tumor growth. Human cells 
carry an intrinsic cell-autonomous program that limits their multiplication in general 
which appears to operate independently of cell-to-cell signaling pathways. Already in 
1965 L. Hayflick observed that normal diploid cells lose their ability to proliferate 
normally after 50-70 cell divisions in vitro. This phenomenon, also known as Hayflick 
limit or cellular senescence, underlies the natural shortening of telomeres during each 
cell cycle caused by the inability of DNA polymerases to completely replicate the 3’ 
ends of chromosomal DNA [13]. If the chromosomes become too short, the cell 
generation enters a state termed crisis which is characterized by karyotypic disarray 
associated with end-to-end fusion of chromosomes and finally massive death. Only in 
germ, stem and certain white blood cells the progressive erosion of telomeres is 
prevented by an enzyme that adds hexanucleotide repeats onto the telomeric DNA, the 
telomerase. It is supposed that normal somatic cells lack of this enzyme to prevent an 
aging cell from becoming malignant. In fact, virtually all types of cancer (85%-90%) [14]  
maintain their telomeres by upregulated expression of telomerase and thus, achieving 
an immortal status. It is assumed that this telomerase overexpressing cells in an 
advanced neoplasm only reflect finally immortalized clones from very few survivors of 
crisis. Interestingly, some malignant cells maintain or even increase the length of their 
telomeres in absence of telomerase activity by a mechanism referred to alternative 
lengthening of telomeres (ALT) [15]. It is suggested that ALT relies on a recombination-
based mechanism whereat single stranded DNA at one telomere terminus invades 
another telomere and uses it as a copy template resulting in exchange and increase of 
sequence information. This inter-telomeric copying may becomes possible through 
abundant displacement loops (D-loops) which normally disrupt base pairing during 
DNA-synthesis at this locus. The exact mechanism of this pathway still needs to be 
clarified. However, circumvention of senescence is a basic necessity for full malignant 
transformation. 
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2.3.5 Sustained angiogenesis 
The oxygen and nutrient supply provided by the vasculature system is crucial for the 
function and survival of any cells. The physiological process involving the formation of 
blood vessels during development, growth and wound healing is referred to as 
angiogenesis. Certain biological signals such as vascular growth factors (VGFs) and 
fibroblast growth factors (FGFs) activate surface receptors present on endothelial cells 
of pre-existing blood vessels initializing them to invade the surrounding matrix and to 
form sprouts towards the angiogenic stimulus. However, already in the late 1960s 
Folkman et al recognized that angiogenesis is a fundamental step in the transition of 
accumulated aberrant cells into a malignant neoplasm [10]. The necessity of blood 
vessel formation within a growing tissue relies on the basic physical issue that oxygen 
and nutrients can only be supplied up to 100μm through passive diffusion. Hence, a 
growing tumor has to acquire the capability of neovascularization which is particularly 
achieved through the common strategy of altered gene transcription. Many tumors 
evidence increased expression of VEGFs and FGFs or the downregulation of 
angiogenic inhibitors such as thrombospondin-1 or β-interferon respectively [16] .  
Further it could be demonstrated that aberrant modulating proteins of pro- and 
antiangiogenic signaling molecules [17] and the dysfunction of onco- or/and tumor 
suppressor genes [18] are involved in the shifted balance of angiogenesis inducers and 
countervailing inhibitors reflecting the complex homeostatic regulation within tumor 
formation that still remains incompletely understood. 
2.3.6 Tissue invasion and metastasis  
The ability to invade adjacent tissue and to give spread to new colonies on distant sites 
is the key characteristic that discerns a benign tumor from malignant cancer. 
Approximately 90% of all human cancer deaths are caused by the distant settlement of 
tumor cells referred to as metastases [19]. Most benign tumors pose little risk to their 
host because particularly cell-adhesion molecules keep them localized to the 
originating tissue, what makes them an easier target for surgical resection. Through 
continuous growth, nutrient supply and space of a tumor become limited factors. The 
capability for invasion and metastasis enables cancer cells to escape these adverse 
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conditions and to colonize new terrains in the body. The genetic and biochemical 
determinants which enable the acquisition of these capabilities during carcinogenesis 
still remain incompletely understood but generally rely on redundant pathways that 
mediate elusion of cells from the primary tumor, survival and arrest in the bloodstream 
and progressive outgrowth at distant locations [20].Invasion is the initiating metastatic 
process that consists of changes in the physical coupling of cells to their 
microenvironment, activation of extracellular proteases and an acquired motility of 
tumor cells to physically move through the tissue. The binding of cells to other cells and 
the extra cellular matrix (ECM) is mediated by cell adhesion molecules (CAMs) such as 
cadherins and integrins. A frequently observed alteration in malignant tumors is the 
inactivation of E-cadherin, a member of the cadherin family that is only expressed on 
epithelial cells. This molecule normally mediates the attachment of cells through 
homophilic protein-protein interactions of their extracellular domains and suppresses 
cellular motility. The intracellular domain of E-cadherin can be attached to β-catenin, 
forming a subunit which serves as intercytoplasmic bridge between cells and may be 
responsible for the transmission of antigrowth signals [11]. It was shown that forced 
expression of E-cadherin in cancer cells in vitro and in vivo impairs their invasive and 
metastatic potential, whereas suppression of E-cadherin function promotes both 
Figure 5. Tumor development: From a normal cel l to malignant cancer [20].   
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capabilities [21]. Another type of signal- and 
attachment-mediating molecules are 
integrins which penetrate the plasma 
membrane and feature small cytoplasmic 
domains. These receptors ensure the 
binding to the ECM that usually provides 
structural support of involved tissue and 
regulates intercellular communication. The 
dysfunction of integrins is associated with 
the recruitment of ECM digesting 
extracellular proteases which provides the 
necessary pathway for invasion [22]. 
Another prominent factor that promotes the 
disintegration of the ECM is the forced 
expression of urokinase or urokinase 
receptors respectively which convert the 
proenzyme plasminogen into the active 
protease plasmin. Generally components of 
the plasminogen activation system are 
found to be correlated with tumor cell 
dispersal [23]. 
Once the anchorage of cells within a 
tumorigenic tissue is loosened and the path 
to nearby blood vessels or the lymphatic 
system respectively is vacated, changes in 
the cytoskeleton can facilitate physically 
movement of aberrant cells. Frequently 
affected targets of mutations are genes 
encoding Rho and other related GTPases 
which are able to drive extensions and 
contractions  of actin/myosin  filaments that 
Figure 6. Two main pathways con-
nect ing inf lammation and cancer:  
The intr insic pathway is act ivated by 
genetic events that lead to the 
production of inflammatory mediators, 
thereby generat ing an inf lammatory 
microenvironment. In the extr insic 
pathway, inflammatory or infect ious 
condit ions augment the r isk of 
developing cancer. Both pathways 
converge and finally force the r ise of 
smoldering cancer-related inflame-
mation that has many tumor-
promoting effects [30]. 
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cause cellular locomotion. In addition, activated N-WASP, a protein that regulates the 
structure of actin filaments, helps to assembly protrusions referred to as invadopodias. 
These structures are very similar to podosomes formed for example by macrophages 
or monocytes, allowing cells to migrate on ECM fibers and to cross tissue barriers or 
penetrate blood vessel walls. 
After entering the circulation system, cancer cells must survive and arrest in the harsh 
environment of the bloodstream for successful extravasation. The presence of immune 
cells, velocity-induced shear forces and the lack of nutrients consequently lead to the 
predominately death of escaped tumor cells. But few survivors of these destructive 
conditions may be able to bind coagulation factors (e.g. fibrinogen, fibrin, thrombin) and 
to arrest as enlarged clots in small capillary beds with help of specific adhesive 
interactions [24]. Generally it has long been recognized that some types of cancer show 
an organ-specific pattern of metastasis referred to as the ‘seed and soil’ hypothesis 
which was first published by Stephan Paget in 1889 [25]. It proposes that the location 
of settlement depends on seed (primary tumor) and soil (secondary organ) specific 
patterns [26]. A second theory suggests that circulatory patterns of the blood flow and 
the lymphatic system between primary tumor and final destination are responsible for 
the organ-specific metastasis of certain malignancies. In fact, both theories are not 
necessarily contrary and can apply according to the type of cancer as more recent 
studies confirm [27]. 
Experimental in vivo models show that metastasis is principally an inefficient process 
because approximately only 1% of injected cancer cells are able to form macroscopic 
tumors [28]. Successful colonization crucially depends on various factors: adequate 
interaction with the microenvironment, cellular structure of the infiltrated tissue as well 
as accumulation of genes necessary for survival and recruitment of growth and 
angiogenic signals within the new location. All these terms demonstrate the enormous 
complexity of metastatic formation, a process that is more and more elucidated but by 
far not completely understood. 
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2.3.7 Cancer related inflammation 
Inflammation-associated cellular effectors and mediators are an important component 
of a tumorous environment. Some types of cancer are related to inflammatory events 
that already occurred before the appearance of malignant changes, others are 
attributed to induce an inflammatory microenvironment that enhances their 
development. Regardless of their diverse origin, inflammatory events are present in 
most, if not all tumors and for this reason are hypothesized to be a seventh hallmark of 
cancer [29].  
The presence of an inflammatory microenvironment within a tumor is thought to be 
established by two different mechanisms: an extrinsic pathway, driven by an 
inflammation that augments the risk of cancer and an intrinsic pathway, driven by 
genetic alterations that lead to inflammatory conditions and neoplasia. The extrinsic 
pathway is associated with an inflammation that has been caused by harmful stimuli 
such as pathogens, irritants or damaged cells. Certain anatomical sites like the colon, 
prostrate, pancreas, liver and lung mesothelium (see asbestosis chapter 2.4.) are 
characterized by a high risk to develop malignancies after chronic inflammation [30]. In 
contrast, the intrinsic pathway generates an inflammatory environment through cancer 
typical aberrations of oncogenes, tumor suppressor genes and the chromosomal 
integrity in tumors for which there is no underlying inflammatory condition (e.g. breast 
tumors). Hence, these facts raise the question why carcinogenesis in general desires 
an inflammatory environment. Both pathways lead to the activation of transcription 
factors - mainly nuclear factor-kb (NF-kb), hypoxia-inducible factor 1α (HIF1α) and 
signal transducer and activator of transcription 3 (STAT3) - which coordinate the 
production of inflammatory mediators like cytokines, chemokines and cyclooxygenase 
2 (COX2) (mediator of prostaglandin production). What follows is the attraction of a 
diverse leukocyte population including neutrophils, dendritic cells, macrophages, mast 
cells and lymphocytes. There is evidence that each of these components can be 
involved in carcinogenesis and/or tumor invasion and metastasis because their 
recruitment is always associated with the release of extracellular proteases, pro-
angiogenic factors and growth signals [31-34]. Normally an inflammation is a self-
limiting process because pro-inflammatory signaling is closely followed by the release 
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of anti-inflammatory factors. If this balance is turned in favor of an abundant production 
of pro-inflammatory cytokines the level of released growth and angiogenic stimuli can 
potentiate the development of neoplasms [30]. Hence, an inflammatory environment is 
frequently recognized in tumorigenic tissues because it can constitute as second type 
of stimulation that promotes the uncontrolled growth of initiated cells. 
On the other hand there is also growing evidence that a chronic inflammation can be 
the origin of a neoplastic transformation. Due to persistent infections or a disrupted 
termination of the inflammatory response leucocytes and other phagocytic cells exhibit 
a prolonged activity and keep releasing toxins such as reactive oxygen (ROS) and 
nitrogen species (RNS) that are normally produced to fight pathogens. These agents 
can react as mutagens, leading to DNA damage and reduced DNA repair. Thus, 
consistent repeated tissue damage and regeneration through healing in the presence 
of these species may result in permanently acquired genomic aberrations, the basis of 
cancer development.  
Naturally the immune system has the assignment to protect the organism against 
diseases by identifying and killing pathogens and also tumor cells. Cancer can only 
occur by successful evading from immune surveillance which is performed through 
multiple pathways. Although the molecular mechanisms are not fully understood, a 
typical alteration of tumor cells are a reduced number of major histocompatibility 
complex class I (MHC class I) molecules on their surface, thus avoiding detection by 
cytotoxic T cells (CTLs) which represent the main defense against aberrant cells [35]. In 
addition, a failed second activation of CTLs, referred to as costimulation, may lead to 
an ineffective immune response. Tumor-associated macrophages (TAMs) are a 
significant component of inflammatory infiltrates in neoplastic tissues and appear as a 
double edged sword. Although they may kill tumor cells, TAMs also produce 
interleukin-10 (IL-10), a cytokine that down-regulates costimulatory molecules. The 
consequence is the development of an immunological tolerance against tumor antigens 
and hence evasion from immune surveillance [36]. Besides suppression of adaptive 
immunity, TAMs express a number of potent vascular endothelial growth factor 
(VEGFs), thereby facilitating angiogenesis and the development of lymphatic vessels. 
Further these factors contribute to the recruitment of monocytes which are the origin of 
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TAMs, thus enhancing their accumulation in neoplastic tissue. Since there is knowledge 
about the wide influence of TAMs and other parts of the immune system on 
carcinogenesis, this issue is suggested to be a point of application in cancer therapy. 
 
 
Figure 7. Modif ied i l lustrat ion of D. Hanahan’s and R. 
Weinberg’s six hallmarks of cancer by Mantovani et al. 
including cancer-related inf lammation as an addit ional 
major attr ibute of cancer development [29]. . 
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2.4 Human Malignant Mesothelioma (HMM) 
2.4.1 Epidemiology and risk factors 
Human Malignant mesothelioma (HMM) is a highly lethal neoplasia that affects the lining 
of certain large serosal body cavities. In most cases mesothelioma is related to 
asbestos exposure although some studies support the role of radiation and the Simian 
Virus 40 (SV40) as causative factors [37-39]. HMM was an extremely rare disease until 
the second half of the 20th century. The incidence of this very aggressive type of cancer 
increased significantly and currently there are about 2.000 to 3.000 cases in the U.S. 
and approximately 10.000 worldwide per year [40].Two-thirds of HMM patients are 
between 50 to 70 years of age. Males are at a much higher risk for this cancer than 
females (70-80%), likely due to occupational asbestos exposure. Especially between 
the 40s and 80s in the U.S. and Europe, asbestos was widely used in the construction 
and shipbuilding industries due to its excellent material properties. The latency period 
between the time of initial exposure and diagnosis of HMM ranges from 20 to 50 years 
and reflects the significant rise of cases in the last decades. In Europe, the anticipated 
peak year of HMM incidence is in the period of 2015–2020, with a predicted incidence 
of 250,000 cases over the next 40 years [41]. 
The incidence of HMM shows noticeable variations from one country to another. The 
hot spots for mesothelioma often exactly correspond to the sites of industries with high 
asbestos use, although many countries which are anticipated for high incidences show 
an unexpected low HMM rate. Further on the one hand it has been proven that around 
80% of patients with HMM in the U.S. have been exposed to asbestos. On the other 
hand epidemiologic studies propose that only 5% with heavy prolonged asbestos 
exposure develop mesothelioma. The reasons for this fact are not clear. It is assumed 
that the different technical approaches used to attribute asbestos exposure worldwide 
may be the principal reason for these discrepant results. However, geographic 
differences, genetic susceptibilities and different distribution of the SV40 between 
populations cannot be excluded as reason for this heterogeneity. 
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Figure 8. I l lustrat ion of estimated annual crude incidence rates of human malignant 
mesothel ioma in the world and some highlighted countries in the table below [40]. 
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2.4.2 Anatomical sites of HMM 
Anatomically HMM is situated within the tunica serosa, a smooth membrane that lines 
and encloses several body cavities and organs [42]. Generally this lining consists of a 
secretory epithelial layer and connective tissue underneath. The latter can be divided 
into the lamina propria serosae which provides blood vessels and nerves and the tela 
subserosae that serves as fat depot. The squamous epithelial layer which is faced 
towards the body cavity produces the lubricating serous fluid that allows the smooth 
movement of enclosed organs. It originates from the mesodermal coelomic epithelium 
and is for this reason referred to as mesothelium. If cells within this layer become 
malignant, the developing tumor is termed as mesothelioma. Overall there are four 
different types of HMM referring to its localisation within the body: 
I. The malignant pleural mesothelioma (MPM) affects 
the serous lining of the thoracic cavity, the two-
layered pleura. The outer parietal pleura is 
attached to the chest wall and the inner visceral 
pleura covers the lung. The thin space between 
both layers is termed as pleural cavity containing 
pleural fluid that averts the lung from collapse. In 
the majority of cases neoplastic development 
arises in one of both layers and can spread into 
adjacent tissues. MPM is the most frequent type 
and affects approximately 70% of all patients [43].  
II. Malignant peritoneal mesothelioma affects the 
serous lining of the abdominal cavity, the 
peritoneum which is divided into a parietal and 
visceral layer like the pleura. The visceral 
peritoneum encloses most inner organs of the 
abdomen such as the liver, gallbladder, spleen, 
stomach and nearly all parts of the small and large 
intestine. Malignant peritoneal mesothelioma is by Figure 10. Peritoneum[42].  
F igure 9. Peritoneum [42]. 
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far less frequent than MPM and affects 10-20% of 
all HMM patients [44].  
III. Pericardial mesothelioma affects the visceral 
(epicardial) and the parietal layer of the serous 
pericardium which contains the heart and the 
roots of the great vessels. Approximately the half 
of all heart tumors are pericardial mesotheliomas 
but only 1-6% of all HMM patients suffer from this 
type. 
IV. Testicular mesothelioma affects the two-layered 
serous tunica vaginalis which covers the testis. It 
represents with about 100 described cases the 
most uncommon type of HMM.    
 
2.4.3 Histological classification 
Based on the diverse constitution of the pleural or peritoneal tissue, human malignant 
mesotheliomas can be classified into three histologic subtypes: epithelioid, sarcomatoid 
and biphasic (mixed epithelioid and sarcomatoid). The epithelioid subtype with an 
incidence of 50-60% is the most frequent, followed by biphasic with 20-40% and 
sarcomatoid with approximately 10% [45]. Several studies have correlated the specific 
subtypes with different survival rates proposing a better prognosis for patients with 
epithelioid mesothelioma [46, 47]. Within the malignant tissue the epithelioid subtype 
can show diverse histological characteristics such as tubulopapillary, microcystic and 
well-differentiated papillary structures with generally well-defined and uniform shaped 
cells. Due to its similarity to another form of cancer known as adenocarcinoma, the 
diagnostic process can be difficult for histopathologists. The sarcomatoid subtype is 
characterized by elongated spindeloid cells, which are typically irregular and not 
uniform in shape. A variety of this subtype represents the desmoplastic mesothelioma 
with bland fibroblastic like cells than sometimes can be misdiagnosed as benign fibrous 
Figure 11. Pericardium[42]. 
F igure 12. Tunica vaginal is 
[42].  
INTRODUCTION
Human Malignant 
Mesothelioma (HMM) 
 
 
34
tissue. The biphasic mesothelioma is the mixture of more or less fractions from one 
subtype. To actually verify the biphasic form, it is important to collect larger tissue 
samples from different locations during biopsy.  
 
2.4.4  The nature of asbestos and its impact on HMM 
Asbestos (from Greek ἄσβεστος meaning “inextinguishable”) is a collective name for a 
group of fibrous silicate minerals that share certain physical characteristics. Those 
include tensile strength, flexibility, sound absorption and its resistance to seawater, 
heat, electrical and chemical damage. Hence, asbestos, the “magic mineral”, was 
especially used for various applications in the construction and shipbuilding industry 
but also e.g. for automobile brake pads, clutch discs, electric ovens and shoes. 
Concerns about the hazardous effects on health of asbestos have been discerned early 
on. Already in 1943 lung cancer as a result of asbestos exposure was recognized as 
occupational disease but it took about 30 years when the first related products were 
banned. In 1987 the International Agency for Research on Cancer (IARC) has classified 
various types of asbestos fibres as human carcinogens (Group I) [38]. Since 1990 
asbestos usage has been entirely forbidden in Austria and since 2005 in the whole 
European Union. Although safer materials have replaced many products that once 
were made of asbestos, a large number of countries still use, import and export 
asbestos and asbestos-containing products.  
Figure 13. Three histological HMM subtypes: (A) epithel ioid; (B) sarcomatoid; 
(C) biphasic [46]. 
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Generally there are six types of asbestos: amosite, crocidolite, anthophyllite, actinolite 
and tremolite, which belong to the group of amphibole minerals, also known as brown 
asbestos and chrysotile that belongs to the serpentine group. The latter is also known 
as white asbestos and has been the most commonly used type. Although the link 
between the development of HMM or lung cancer respectively after asbestos exposure 
is generally accepted, the relative carcinogenicity of the various fibre types and a dose 
response relationship remain controversial. Some studies showed that larger fibres, 
such as amphibole, rather accumulate in the lung tissue, while shorter fibres, mainly 
chrysotile, were found in the pleura, suggesting that the latter may be predominantly 
responsible for the development of HMM [48]. Although these results appear 
Figure 14. (A) In 2006 the product ion of asbestos was est imated at 2.3 mil l ion tons, 
with approximately 40% of that being mined in Russia. I l lustrat ion shows further hot 
spots of asbestos production around the globe. (B) Asbestos Fibers using a Scanning 
Electron Microscope [38]. (C) Lodged asbestos f iber in a human lung [38].   
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conclusive, to date there is not sufficient evidence to exactly associate certain fibre 
types with the development of cancer on specific sites [38]. Also the dose of asbestos 
required for a malignant outcome remains uncertain, not least because historical 
studies are based on interviews with patients which represent an unsatisfying source 
for scientific dose evaluations. Since the determination of asbestos exposure is based 
on different methods and inter-laboratory comparisons are unreliable because of 
heterogeneous procedures, controversial conclusions may remain. 
The link between asbestos and HMM is highly supported by numerous animal studies. 
The majority of all in vivo experiments are based on the intrapleural and intraperitoneal 
injection of asbestos resulting in a dose dependent outcome of malignant pleural and 
peritoneal mesothelioma [49-51]. Although these injection experiments propose 
plausible results, they have been criticized because that way of exposure differs 
vehemently from the actual process. Hereby the most discussed issue is the bypassing 
of clearance and lung defence mechanisms leading to unrealistic heavy accumulations 
of asbestos in the pleura and peritoneum. For this reason also chronic inhalational 
experiments have been applied which today represent the best comprehensible in vivo 
studies on asbestos carcinogenicity. Depending on exposure duration and used 
species these experiments resulted in mesothelioma incidences from 1.2-20% [48, 52]. 
However, mesothelioma development was not significantly affected by the fibre type as 
it has been observed in injection studies. Regarding to dose response curves, all animal 
studies suggest that mesothelioma development is directly related to the amount of 
asbestos exposure and that tumors will not develop below a certain threshold level 
[53]. In contrast epidemiological studies in human do not support this observation [54]. 
2.4.4.1 Molecular mechanisms of asbestos induced HMM development  
The molecular mechanisms of asbestos pathogenicity are not fully understood. 
However, with the extensive work of in vitro and in vivo model systems direct and 
indirect mechanisms of asbestos induced mesothelioma have been proposed. 
Direct mechanisms of asbestos related carcinogenesis can be generally separated into 
genotoxic and nongenotoxic pathways. The basic toxic characteristic of asbestos 
fibres relies on the appearance of reactive oxygen species (ROS) which are known as 
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high class mutagens. It is hypothesized that clearance mechanisms that try to solubilize 
inhaled fibres cause the release of asbestos containing metals such as iron. Those may 
serve as oxidation-reduction catalyst in a Fenton-type reaction to produce ROS [55]. 
Since amphiboles are not soluble, this theory may only apply to chrysotile. In fact, 
amphibole fibres are thought to serve as sites of precipitation within the tissue through 
their unfeasible removal. After a period of time the fibres become coated with iron-rich 
material and minerals trough mineral-fluid interactions. What follows is the formation of 
particles known as asbestos bodies or ferruginous bodies with radically changed 
surface characteristics of the fibres. Consequently this surface can serve as catalyst 
between fluid constituents changing their physical properties which may lead to an 
aberrant and dysfunctional fluid chemistry [38]. 
It has been shown that asbestos fibres can also mechanically interfere with the mitotic 
spindle, chromosomal segregation, and cytokinesis in cell culture [56-59]. 
Consequences are altered chromosome morphology and ploidy as well as produced 
DNA strand breaks. These in vitro studies have been confirmed by several animal 
experiments which showed increased mutation frequencies [60] and elevated levels of 
hydroxyl [61] and lipid radicals [62] in affected tissues, after asbestos injection or 
inhalation.  
According to direct nongenotoxic effects after both, chronic and acute asbestos 
exposure, an increased proliferation of epithelial and mesothelial cells accompanied by 
activated growth factor receptors and intracellular signaling pathways have been 
generally observed [38]. This has been confirmed in human and rodent mesotheliomas 
which show a frequently constitutive expression and activation of growth-factor 
pathways including those of insulin-like growth factors (IGFs), platelet-derived growth 
factor (PDGF), vascular endothelial growth factor VEGF, and transforming growth factor 
beta (TGF-β) [38]. Responsible mechanisms remain uncertain. However, it is known 
that ROS-mediated injury and/or direct physical damage of cells through contact with 
asbestos fibers trigger apoptosis or necrosis. This cell death may be hyper-
compensated by enhanced repair and cell proliferation within affected tissue. A 
continuous repeat of cell injury and repair may give rise to accumulation of mutations 
especially in the presence of a toxic environment. This could expand a preneoplastic 
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proliferating cell population during the early stages in the development of HMM [38]. 
Indirect mechanisms of asbestos carcinogenesis are believed to rely on a triggered 
chronic inflammation, a hallmark of cancer. The permanent inflammatory response is 
caused by persistent fibers within the tissue which are countered by activated 
macrophages through the release of ROS and NOS. This secondary induced toxicity 
may triggers mutations within proliferating cells and enhances the development of 
HMM [63]. Furthermore, epigenetic silencing of tumor suppressor genes after asbestos 
exposure has been described in HMM [64-66]. This is supported by the fact that ROS 
have also been proposed to contribute to altered DNA methylation [67, 68]. 
Several cofactors with asbestos fibers in the induction of HMM such as tobacco 
smoke, ozone inhalation and the SV40 are still subject of controversial discussions. 
Acquired genomic aberrations especially of key genes involved in DNA repair after 
asbestos exposure may facilitate accumulation of further mutations by tobacco-smoke 
carcinogens [38]. Ozone inhalation was at least shown to impair clearance and 
increase retention of asbestos fibers in the lungs of rats [38]. 
2.4.5 Possible relations of SV40 and HMM 
The Simian virus 40 (SV40) is a DNA virus that has been assigned to processes in 
cancer development especially of HMM. It belongs to the family of polyomavirus and is 
thought to be endogenous in rhesus monkeys while epidemiological studies have 
shown that it is now widespread among the human population. A possible transfer 
from monkey to human may has occurred between 1955 and 1963 when 
contaminated polio vaccines were applied to millions of people [69]. Also the 
contagiously transmission by horizontal infection through hematic, sexual, and orofecal 
routes is suggested by epidemiological evidence [69]. 
The mechanisms of SV40 tumorigenesis in human are only partially understood. 
Generally it has been shown that SV40 expresses two viral oncoproteins, the large T 
antigen (Tag; 90kDa) and the small t antigen (tag; 17kDa) which are able to block 
certain proteins involved in cell cycle regulation. Tag is capable of binding to the major 
tumor suppressor proteins p53 and Rb and consequently inhibits their regulatory 
function of inducing apoptosis and/or cell cycle arrest when a cell is damaged. More 
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than 50% of all human tumors contain a mutation or deletion of the p53 encoding gene 
TP53 [70] verifying its enormous importance in preventing from cancer. Furthermore, 
Tag was shown to be responsible for chromosomal aberrations in host cells and also 
induces insulin like growth factor (IGF), a hormone that stimulates cell proliferation [71]. 
The main function of the small tag is the inhibition of the protein phosphatase PP2A 
whose major targets belong to signaling cascades such as Raf, MEK, AKT and Wnt 
which are frequently deregulated in proliferating malignant cells. 
The link between SV40 and development of HMM has been a particularly controversial 
area of research because in this point opinions range from strong to no evidence for a 
causal relationship. Several studies detected SV40 viral DNA sequences in up to 80% 
of HMM [71] but this findings have been partly refuted based on technical concerns by 
some investigators. Upon others López-Ríos et al. showed evidence against a role for 
SV40 infection in HMM and claimed high risk of false-positive PCR results because of 
the presence of SV40 sequences in common laboratory plasmids [72]. Also a cross-
reactivity of serologic tests with related viruses such as BKV (Human Polyomavirus 1) 
and JCV (Human Polyomavirus 2) is discussed to produce false positive results. These 
viruses also belong to the family of polyomavirus and are very common in the general 
population, infecting 70–90% of humans but do not cause disease in immune-
competent individuals. Recently development of more sensitive tests which are based 
on RT-PCR assays that are specific for SV40-encoded microRNAs (miRNAs) were 
unable to identify an expression of these markers in HMM samples [73]. However, 
some in vitro and in vivo experiments propose an association between SV40 exposure 
and HMM development. Human mesothelial cells were shown to have a different 
susceptibility to infections with JCV, BKV and SV40. While JCV did not infect the 
targeted cells, BKV caused mesothelial cell lysis. Only the infection of SV40 resulted in 
high rates of malignant transformed mesothelial cells indicating its actual presence in 
former analyzed HMM specimen rather than the ubiquitous human JCV and BKV [74]. 
In animals, SV40 was shown to be a strong carcinogen causing the development of 
mesotheliomas in nearly 100% of hamsters following intrapleural injection or 60% 
following intracardial exposure respectively [75]. In contrast, transgenic mice that 
express SV40 Tag in the mesothelial compartment showed a relatively low level of 
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spontaneous tumor development. Interestingly, when these mice were exposed to 
asbestos they rapidly developed mesotheliomas which were faster growing and more 
invasive than asbestos induced tumors in wild-type mice. Additionally in vitro analyses 
demonstrated that SV40-transfected human mesothelial cells exposed to asbestos 
maintain a malignant transformed phenotype while wild-type cells died rapidly due to 
asbestos cytotoxicity [76]. These data indicate a co-carcinogenicity between SV40 and 
asbestos in the development of mesotheliomas at least in in vitro and in vivo 
experiments. However, these results are not sufficient to prove causality. Further 
epidemiological studies and analyses of tissue specimen have to be performed to give 
deeper insight into the role of SV40 in HMM. 
2.4.6 Diagnosis of HMM 
In case of a clinical suspicion of thoracic/pleural HMM, the endoscopic examination of 
thorax (thoracoscopy) or peritoneum (laparoscopy), respectively, with an attendant 
biopsy represents the most important procedure to prove diagnosis. Modern imaging 
via computed tomography (CT), magnetic resonance tomography (MRT) and/or 
positron emission tomography (PET) is also a common part of the diagnostic process 
[77-79]. The mode of subsequent therapy depends on the specific parameters given by 
examination. The progress level of MPM is staged referring to the commonly used TNM 
classification of malignant tumors [80]. This system describes the size of tumor (T) and 
whether it has invaded nearby tissue/organs, the involvement of nearby lymph nodes 
(N) and the appearance of distant metastases (Tab.2). Today there is no standard 
staging system for peritoneal mesothelioma or other types of HMM. 
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Table 2. Internat ional TNM staging system for MPM [80]. 
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Figure 15.  (A) Image shows a typical 
axial CT scan of the chest with 
irregular nodular pleural thickening in 
the right hemithorax [77]. (B) PET-
scan of the thorax from another 
patient suffering from MPM [78]. (C) 
Intraoperative photograph of a diffuse 
peritoneal malignant mesothel ioma 
shows numerous tumor nodules 
(arrows) scattered over the omental  
surfaces [79]. 
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2.4.7 Etiopathology and prognosis of HMM 
In the majority of cases HMM is diagnosed at progressed stage because of very 
unspecific symptoms like shortness of breath (dyspnea), cough and abdominal or 
thoracic pain. Unfortunately these symptoms do not occur until a relatively advanced 
tumor progression and thus most cases of HMM are primary diagnosed at stage II.  For 
this reason mostly only palliative therapy with the objectives of prolonging lifetime and 
improving quality of life can be offered. Only few patients are considered of surgical 
tumor resection with a curative intention. Although this collective features a better 
prognosis, the five-year survival rate of this patient group lies below 15% in case of 
MPM [81]. The median survival time of patients with adverse prognosis lies between 
five and eight months, those with favorable prognostic parameters survive between ten 
and eighteen months in case of MPM [82]. Normally respiratory insufficiency and 
secondary pneumonia are the actual causes of death. Patients diagnosed with 
malignant peritoneal mesothelioma obtain comparable median survival rates with 
approximately one year [83]. These poor prospects show that the development of new 
and more efficient treatment options is urgently needed. 
2.4.8 Current therapy of HMM 
Due to the prevalently multifocal and diffuse expansion of HMM only very extensive 
surgical resections result in a detectable survival improvement. However, in the last 
years the perioperative mortality dropped under 10% because of more advanced 
surgical techniques and post-surgical treatment in specialized clinics [84]. To improve 
therapeutic success multimodal therapies are always preferable to sole surgery. At the 
moment only the combination of resection, chemo- and radiotherapy provides the best 
possible way to enhance survival of MPM patients. In case of malignant peritoneal 
mesothelioma cytoreductive surgery (CRS) combined with perioperative intraperitoneal 
chemotherapy (PIC) is proposed to be the best standard of care to this date [85]. 
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2.4.8.1 Surgery 
The goal of surgery is to provide a macroscopic resection of all grossly visible tumors 
as completely as possible. In case of MPM two different operative techniques have 
evolved: extrapleural pneumonectomy (EPP) and pleurectomy/decortication (P/D). EPP 
involves the removal of the affected parietal and visceral pleura, the complete 
underlying lung, parts of the diaphragm and pericardium. P/D represents a less 
extensive surgery in which the lung is left in place and only parietal and visceral pleura 
are resected [86]. Within both methods the removed linings are replaced by prosthetic 
material (usually Gore-TexTM) granting a breathable and protective compensation. 
Figure 16.  (A) Extrapleural pneumonectomy: First chest retractors are placed to 
increase access to the in it ial exposure of the tumor. A nasogastr ic tube is 
inserted in the esophagus to prevent in jury while the tumor is being resected off 
the esophagus. Then the diaphragm is avulsed or bluntly separated from the 
chest wall muscular attachments. (B) Pleurectomy/decorticat ion: The second type 
of surgical intervent ion is accomplished in two stages. First, the tumor is incised 
posteriorly to the hilum and a plane is developed between the visceral pleura and 
the underlying lung parenchyma. The fully decort icated lung is retracted out of 
the lower tumor shel l and removed from the operat ive field. In this case the 
diaphragm stays intact [85].  
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The choice of applied technique relies on the tumor characteristics, whether the patient 
can tolerate the surgery and which procedure achieves a macroscopically complete 
resection. In case of malignant peritoneal mesothelioma which represents a relatively 
rare clinical entity, there is no standardized surgical procedure at the moment. 
Operations for this type of HMM are generally based on an extensive tumor debulking 
reducing all foci to a microscopic level. An accompanying complication of such 
operations in all cases may be a widespread hematogenous or lymphangogenic 
dissemination of microscopic tumors [85]. Additionally in some parts of the chest it is 
not possible to remove the neoplastic tissue including sufficient surgical margins. The 
frequent consequence is a recurrence of the tumor at local sites or even at former 
uninvolved areas within the body. Thus, the treatment of microscopic residuals with 
adjuvant therapy is essential.  
2.4.8.2 Radiation therapy 
The principal mechanism of radiation therapy relies on the induction of DNA lesions in 
cancer cells which generally are characterized a deficiency in error correcting 
mechanisms. Ionizing high-energy rays generate toxic ROS in the focused area and 
lead to inhibition of cell-cycle progression mainly induced by DNA double strand 
brakes. Radical radiation therapy shows excellent benefits in certain cancer types [87, 
88], but unfortunately not in the treatment of MPM and malignant peritoneal 
mesothelioma. Due to critical organs such as the lung, heart, esophagus and liver in 
the hemithorax, the administered total dose of radiation is limited. Several studies have 
shown that hemithoracic irradiation alone results in significant toxicity leading to 
hazardous inflammations of affected tissues without any survival benefit [89]. For this 
reason, currently there is no evidence to support the use of radical radiation therapy 
alone, administered with curative intent, in the management of patients with MPM [89, 
90]. Hence, this kind of antineoplastic treatment is only applied within a multimodal 
therapy regimen as perioperative option to prevent fast relapse of microscopic tumor 
residues or in fewer cases as palliative care. Due to hardly any benefits of radiation 
therapy on malignant peritoneal mesothelioma patients, this treatment option is 
generally not applied in this case [91].     
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2.4.8.3 Chemotherapy 
With respect to disseminated cancer, chemotherapy in general is the cytotoxic or 
cytostatic treatment of tumors using chemicals which mostly work by impairing mitosis 
or inducing apoptosis in fast dividing cells. As cancer cells reveal increased proliferative 
rates and deficiency in error correcting mechanisms, they show a higher susceptibility 
to such agents than healthy cells.  Some types of neoplastic disease show an excellent 
response to chemotherapeutic treatment regimens, especially in early stages, and are 
able to enhance the chances of cure [92-94]. Unfortunately, HMM exhibits only a 
moderate chemo-sensitivity. Older chemotherapeutic agents such as cisplatin and 
adriblastin only achieved response rates below 20% [95]. In the last years, newer drugs 
such as pemetrexed, gemcitabine, vinorelbine and oxaliplatin extended the lineup of 
agents and improved tolerability but did not show significantly increased response rates 
in monotherapy regimen. Within a randomized phase III trial including a cohort of 456 
patients the combined treatment with cisplatin and pemetrexed showed a significant 
advancement compared to cisplatin monotherapy referring to response rate (41.3% 
versus 16.7%) and median survival (12.1 months versus 9.3 months) [96]. Currently this 
combined treatment represents the standard chemotherapy for patients in good 
general condition.  
The cytotoxic effects of cisplatin (cis-diamminedichloroplatinum(II)) was already 
discovered in 1965 by Barnett Rosenberg when he noticed that electrolysis of a 
platinum electrode produces cisplatin which inhibits binary fission in E.coli by disrupting 
cell division [97]. Generally it is accepted that the effects of cisplatin arise from binding 
the DNA causing crosslink adducts that on the one hand interfere with DNA synthesis 
during mitosis and on the other hand trigger apoptosis due to blocked DNA repair [98]. 
Figure 17. Formation and effects of cisplat in adducts. The plat inum atom of cisplatin 
binds covalent ly to purines to form intra- and interstrand crosslinks [97]. 
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Recently it has been shown that the mechanisms involved in the cytotoxicity of cisplatin 
are much more complex than DNA damage alone. It is proposed that cisplatin can 
directly interact with regulatory proteins [99] and the plasma membrane [100] leading to 
the dysfunction of certain signaling pathways. Moreover there is evidence that cisplatin 
induces the formation of ROS representing an additional trigger of cell death [101]. 
In the majority of cases chemotherapeutic drugs are systemically applied and pass 
several body tissues. For this reason also cells that divide rapidly under normal 
Molecular mechanisms Consequence 
Decreased drug uptake (e.g. downregulation of copper 
transporter CTR1) Reduced intracellular platinum 
Increased drug efflux (e.g. overexpression of cMOAT and 
copper transporters: ATP7A, ATP7B)  
accumulation 
Increased level of GSH and increased activity of GSH-related 
enzymes 
Reduced bioavailability of  
platinum 
Increased level of metallothioneins 
 
Alterations in mismatch repair Increased DNA repair capacity 
and/or increased capacity to 
Alterations in nucleotide excision repair 
replicate through adducts
Alterations in anti-apoptotic factors (e.g., BCL-2 and IAPs) Failed induction of 
cell death 
Alterations in pro-apoptotic factors (e.g., p53, caspases, Fas, 
BAX, and BAK)  
Alterations in the MAPK cascade pathway  
Alterations in the PI3-K/Akt signaling pathway  
Alterations in transcription factors  
Alterations in cell cycle–related factors Varies depending on the 
altered factor(s) 
Table 3. The primary molecular mechanisms involved in cisplat in-resistance [100].  
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Figure 18. Pemetrexed inhibits mult iple 
targets involved in both pyrimidine and 
purine synthesis [102]. 
circumstances as for example in the bone marrow, digestive tract and hair follicles, are 
harmfully affected. Hence, cisplatin and other related chemotherapeutic agents cause 
severe side effects. Another application limiting factor represents intrinsic and acquired 
resistance leading to a low responsiveness or tumor relapse, a fact that is frequently 
observed in HMM treatment [102]. Several molecular mechanisms that can be 
activated by tumor cells to survive cisplatin treatment have been described (Tab.3). 
Upon other, upregulated expression of efflux transporters and/or decreased level of 
uptake activity are proposed to be mainly responsible for a reduced intracellular 
platinum accumulation causing the ineffectivity of chemotherapy. Furthermore cisplatin-
resistant tumors are suggested to obtain increased DNA repair and tolerance of DNA-
damage which may be responsible to finally overcome cell death. 
For the treatment of HMM the 
chemotherapeutic antifolate pemetrexed 
is generally recommended to be applied 
with cisplatin, as the combination 
showed more efficiency than either drug 
alone [96]. Since folic acids are essential 
for the biosynthesis of certain 
nucleotides and methyl groups, their 
functional inhibition consequently impairs 
DNA and RNA synthesis as well as DNA 
repair. Like most other antifolates, 
pemetrexed is a folic acid analogue that 
is able to bind folate-metabolizing 
enzymes which normally progress the 
formation of precursor purine and 
pyrimidine nucleotides. Because 
replicating cells depend on the supply of these basic DNA units, pemetrexed is 
cytotoxic during the S-phase of cell cycle especially in fast dividing cancer cells [103]. 
However, like in the case of cisplatin also normal cells are toxically affected leading to 
their dysfunction or apoptosis and causing adverse reactions. To some extent these 
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side effects can be attenuated by high folate diets and supplemental folic acid. 
Although pemetrexed and other antifolates can lead to neoplastic cell death their long 
term effectiveness is diminished by cellular response. Over a period of time cells can 
compensate the blocked enzymes by e.g. increasing their expression and thus 
acquiring resistance to pemetrexed [104]. Some examples of molecular alterations 
concerning acquired pemetrexed-resistant are listed in Table 4.     
 
 
Molecular alteration Example 
 
Qualitative and/or 
quantitative alterations in 
influx and/or efflux 
transporters of (anti)folates 
 
inactivating mutations and/or down-
regulation of reduced folate carrier 
(RFC) which is predominantly 
responsible for the cellular uptake of 
pemetrexed 
 
Qualitative and/or 
quantitative alterations of 
folate-dependent enzymes 
 
the target enzymes dihydrofolate 
reductase (DHFR), thymidylate synthase 
(TS) and folylpoly-γ-glutamate 
synthetase (FPGS) 
 
Overexpression of multidrug 
resistance proteins which 
may cause resistance to 
other anticancer drugs  
 
Active efflux of drugs and cellular toxins 
by members of the ATP-binding 
cassette (ABC) transporters including P-
glycoprotein (Pgp/ABCB1), multidrug 
resistance proteins (MRPs/ABCC) as 
well as breast cancer resistance protein 
(BCRP/ABCG2) 
 
 
Table 4.  Molecular alterations involved in pemetrexed-resistance [103]. 
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Figure 19.  The il lustration shows a variety of 
monoclonal antibodies and their specif ic 
targets on the cel l surface. Their f ield of 
applicat ion can be general ly separated into 
two dist inct classes of cancer: hematologic 
malignancies and solid tumors [104].   .   
2.5 Targeted therapy 
Although in the last decades the research on cancer beard advanced treatment 
strategies it is generally accepted that current therapeutic options, which are still 
predominantly based on chemotherapeutic agents, are limited. For this reason a large 
field of contemporary research focuses on investigative attributes unique for cancer 
cells that my present key alterations of the malignant phenotype. This novel strategy of 
cancer treatment is generally termed “targeted therapy”, which is based on the 
interference with critical molecular pathways of tumors to inhibit their growth and force 
their demise [105]. In contrast to conventional chemotherapy this strategy is believed to 
be more effective against the actual source of malignancy attaining a better outcome 
for patients while reducing severe side effects. Experiences showed that most types of 
cancer are characterized by sets of different molecular changes responsible for their 
development and progression. For 
this reason one of the major 
challenges is to reveal essential, 
cancer type-specific altered signal 
pathways, to gain more inside into 
their role in malignant progression 
and to find compounds that directly 
target involved molecules. 
By now two main categories of 
targeted therapeutics have been 
developed, monoclonal antibodies 
and small molecule inhibitors. The 
therapeutic effect of monoclonal 
antibodies is based on their binding 
to specific cell surface molecules or 
extracellular receptor ligands. In 
addition to target inhibition, mono-
clonal antibodies are able to induce 
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a mechanism referred to as antibody-dependent cell-mediated cytotoxicity (ADCC). 
This part of the adaptive immune response is mediated by effector cells of the immune 
system such as natural killer (NK) cells, neutrophils and eosinophils which actively lyse 
target cells that in this case have been labeled by monoclonal antibodies. Although this 
strategy is still under development, few drugs have already been licensed for clinical 
use (Fig.19) due to their enormous benefits to the treatment of some neoplastic 
diseases [106-110]. The second main group of agents is referred to as small 
molecules, a very general term in the fields of pharmacology and biochemistry for drugs 
that are able to rapidly diffuse across cell membranes and take effect on intracellular 
key players. Generally their aim is to interfere with aberrant signal transduction that 
leads to uncontrolled cell proliferation followed by metastasis, apoptosis resistance 
and/or tumor associated angiogenesis [111]. As attained chemotherapy resistance of 
cancer cells is also maintained by aberrant signaling pathways, targeted therapy may 
also be used to restore sensitivity to certain chemotherapeutical agents. Actually some 
targeted compounds are already in clinical use showing enhanced respond rates, less 
Figure 20. Overview of different molecular targets of small molecules and the 
involved signal ing pathways hit by targeted therapy [104]. 
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Figure 21. Overview of mult iple 
factors affecting mTOR and the 
result ing cel lu lar responses [115]. 
side effects and prolonged survival of patients [112-114]. However, their field of 
application is limited only to certain malignancies and the effectiveness shows a broad 
variation.  One of the main reasons for this issue is the still only superficial knowledge 
on key carcinogenic players and most notably their interactions with networking 
pathways. Thus the inhibition of one target may lead to the reinforcement of other 
signaling cascades allowing survival of cancer cells. Thus, a better understanding of 
reactions triggered by the interference with one targeted molecule may lead to 
improved therapeutical success. Further, patients with the same malignant disease 
might harbor tumors with different genetic mutations. Consequently inhibition of a 
specific molecule may lead to an enormous benefit for one patient but show only 
marginal effects for another due to the insignificance of the targeted pathway in this 
tumor. For example patients with chronic myelogenous leukemia (CML) show a 
dramatically improved survival after treatment with the small molecule imatinib when 
they were positive for Philadelphia chromosome [115]. Here the therapy relies on the 
inhibition of a critical molecular driver, the bcr-abl protein which is constitutively 
activated in 95% of all patients. Unfortunately cases with such a define target are rare 
especially in solid tumors. Nevertheless, this phenomenon, called “oncogene addiction” 
may be also present in other malignancies. Hence, their identification will be one future 
focus of targeted therapies, although may be combined treatment strategies will be 
required to prevent the escape of tumors 
from this “subjection”.   
2.5.1 mTOR and its role in normal cells 
During the last years an increasing number of 
molecular pathways which are strongly 
involved in oncologic signaling have been 
revealed. One of the most important 
represents the PI3K (phosphatidylinositol 3-
kinase) pathway which is intracellularily 
mediated by AKT-kinase, one of the main 
activators of mTOR. In normal cells the 
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Figure 22.  Activat ion of mTOR. The GTPase Rheb activates mTOR and is in turn control-
led by TSC1 and TSC2. The interaction of TSC proteins with Rheb is affected by signals 
from growth factors, amino acids, adhesion proteins and energy levels. AMPK is act i-
vated by an increase in AMP and activates TSC2, which inhibits Rheb. LKB1 addit ional ly 
promotes the act ivat ion of AMPK in turn of low energy levels [115]. 
mammalian target of rapamycin (mTOR) is a kinase that acts as biological switch and 
helps to mediate an adequate response to changes of the cellular environment. It is 
linked to the upstream PI3K pathway that senses nutrient and energy levels, growth-
regulating factors and cellular stress. mTOR mediates these signals as a master 
operator that regulates cell proliferation, cell survival, protein synthesis, and 
angiogenesis. In this manner, mTOR on the one hand forces anabolic processes and 
on the other hand prevents cells from proceeding when certain factors are not sufficient 
to support the effort [116].  
2.5.2 Control mechanisms of mTOR 
Reflecting the multiple roles of mTOR, its regulation is necessarily complex and involves 
several well-defined factors whose interaction with other molecules and signal 
pathways are still not fully understood. According to the current model, the main mTOR 
regulatory molecules include the tuberous sclerosis complex TSC1 (hamartin) and 
TSC2 (tuberin), which are able to form a heterodimer that inhibits mTOR activity [117]. 
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When AKT-kinase, which is indirectly stimulated by growth factors, phosphorylates 
TSC2, the TSC heterodimer dissociates and thereby allows TSC2 to activate the small 
GTPase Rheb in turn to upregulating mTOR activity. Interestingly phosphorylation of 
TSC2 by AMPK (5' AMP-activated protein kinase), a regulator of cellular energy 
homeostasis which is activated through energy deficiency, forces the inactivation of 
Rheb and consequently the inhibition of mTOR activity [118]. Hence, on one hand 
indirect stimulation by growth factors results in mTOR activation and on the other hand 
low energy levels lead to its inhibition. Both situations are mediated by the same 
molecules, TSC2 and Rheb, depending on specific upstream factors. 
Activation of mTOR subsequently allows the formation of the nutrient- and energy-
sensitive  mTOR Complex1 (mTORC1) which is at least composed of mTOR, regulatory 
associated protein of mTOR (Raptor) and G-protein β-subunit like protein (GβL). This 
complex controls mTOR activity by regulating the accessibility of its kinase domain to 
mTOR-substrates depending on the nutrient and energy supply in the cell [116]. The 
exact mechanisms involved in the sensing of nutrient and energy levels are still widely 
unknown and remain to be explored. 
Besides the afore mentioned regulatory function of mTOR involved in cell growth and 
protein synthesis, it has been shown that this molecule is also associated with the 
formation of the cytoskeleton through its stimulation of F-actin stress fibers, RhoA, 
Rac1, Cdc42, paxillin and protein kinase C α (PKCα) [119-121] . Interestingly this 
functions are only mediated by another mTOR involving complex, mTORC2, which is 
composed of mTOR, rapamycin-insensitive companion of mTOR (Rictor), GβL, and 
mammalian stress-activated protein kinase interacting protein 1 (mSIN1). The 
regulatory mechanisms of the complex associated proteins related to mTOR activity 
are not fully understood but appear to be stimulated by nutrients, growth factors and 
insulin. 
2.5.3 Aberrant upstream mTOR-signaling and its relation to cancer 
A multitude of critical molecules involved in the regulation of mTOR upstream pathways 
are known to be frequently deregulated to a certain extant in cancer. This leads to a 
number of potential defects that can cause an inappropriate activation of mTOR-
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signaling finally causing growth and proliferation of malignant cells. Due to the key 
position of mTOR in the transduction of aberrant signals, blocking their effects at the 
point of convergence is a rational approach and a promising cancer treatment strategy. 
Aberrant mTOR signaling can obtain its origin from upstream deregulated growth factor 
receptors in the cell surface which maintain inappropriate signaling due to 
overproduced growth factors or mutations/translocations that lead to their constitutive 
activation or overexpression [122]. Also the dysfunction of cytokine and integrin 
receptors is a common characteristic of cancer cells [11]. Aberrant messages from 
receptors on the cell surface are then transduced to intracellular signaling pathways 
whose importance can vary depending on the cell type and therefore are often 
associated to specific malignancies. The PI3-K/AKT pathway is commonly deregulated 
in a series of cancer types and associated with tumor progression and increased 
metastatic ability [123, 124]. Independent of any receptor stimulation, PI-3 kinase can 
be overactivated by intracellular signaling such as from oncogenic mutated RAS which 
is found in 20-25% of all human tumors [125]. Also mutations in PIK3CA, the gene for 
the catalytic subunit of PI-3 kinase have been reported in many cancers [126] and are 
responsible for its constitutive activation. 
A negative regulation of the PI3-K/AKT pathway is essential for a healthy cell to 
maintain control of its own proliferation and growth and is particularly provided by the 
phosphatase enzyme PTEN (Phosphatase and Tensin homolog on chromosome 10). It 
removes the phosphate groups added by PI-3 kinase to its substrates and 
consequently turns off subsequent signaling. However, PTEN is one of the most 
frequently lost tumor suppressors in several cancer types [127] which reflects the 
fundamental significance of this pathway in malignant progression.  
Another critical kinase that mediates its regulatory function through mTOR stimulation 
represents AKT, a key player associated with cell growth and survival. Activating 
mutations of AKT are frequently found in several cancer types and help to maintain 
antiapoptotic signaling [123]. It is believed that constitutively activated AKT counteracts 
apoptotic programs in response to the genetic insults caused by chemotherapy and 
therefore maybe contributes to drug resistance. This demonstrates again that blocking 
the signaling downstream of over activated AKT seems to be a reasonable therapy 
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strategy and has been confirmed by several studies showing a correlation between the 
presence of activated AKT and sensitivity to mTOR inhibitors [128, 129]. 
 
2.5.4 Influences of mTOR on protein synthesis and cell proliferation 
mTOR is known to be responsible for the regulation of more than 100 genes, many of 
which are involved in cell growth and cell proliferation-associated processes [130]. It 
acts at the level of gene transcription and protein translation and provides for this 
reason a rapid response to changes in the cellular environment and situations of stress. 
The direct targets of mTOR are the serine/threonine kinase P70-S6K1 (Ribosomal 
protein S6 kinase beta-1) and 4E-BP1 (4E-Binding Protein 1), a member of translation 
repressor proteins. mTOR phosphorylates P70-S6K1 which in turn phosphorylates the 
ribosomal protein S6 that activates the translation of 5’terminal oligo-pyrimidine (TOP) 
Figure 23. Schematic overview of connected oncogenic pathways 
involved in mTOR signal ing. Only some of the molecules of known 
funct ions and importance are shown. AKT is part icularly important 
because of its role in modulating the mTOR pathway and maintaining 
of ant iapoptotic signal ing [115].   
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Figure 24.  mTOR controls 
ribosome biogenesis and CAP-
dependent mRNA translation 
[115].  
mRNAs. Critical components of the protein translation machinery such as ribosome 
forming proteins, elongation factors (eEF1A, eEF2) and the poly(A)-binding protein 
(PABP) are coded by these TOP mRNAs. mTOR represents the regulatory molecule of 
all these factors due to its sensing of amino acid concentration within the cell which are 
essential for translation [131]. The inhibition of mTOR allows the phosphatase PP2A to 
inactivate P70-S6K1 and consequently stops the synthesis of ribosomes and proteins 
involved in metabolic processes. 
The phosphorylation of 4E-BP1 by mTOR causes the release and thus the activation of 
eIF-4E (eukaryotic Initiation Factor 4E) which forms with other initiation factors the CAP-
mRNA recognizing complex eIF-4F. These CAP-mRNAs obtain a 7-methyl guanosine 
nucleotide triphosphate ‘cap’ at their 5’end and polyadenosine tail at their 3’end. The 
eIF-4E complex brings together ribosomes and the 5’ends of CAP-mRNAs and 
therefore initiates the translation of key proteins that regulate cell cycle, cell growth and 
survival. The key role of mTOR in regard to the transduction of signals leading to the 
translation of these proteins may even more significantly related to the progression of 
cancer than the activation of P70-S6K1, as data suggest [132]. 
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2.5.5 Influences of mTOR on cell cycle progression 
The translational activity forced by mTOR involves a large amount of different mRNAs 
including those coding for cyclins (cyclin D1) which regulate the activity of cyclin-
dependent kinases (CDKs) thus driving the cell cycle [133]. Normally cyclin D1 is 
synthesized during G1-phase and drives the transition into S-phase if the cell is 
sufficiently supplied with nucleotides and necessary enzymes. Overexpression of cyclin 
D1, which is the case in many cancer types, can lead to a shortened G1-phase and 
drives the cell through the G0/S checkpoint, even when the necessary growth factors 
are not present. In addition, there is evidence that cyclin D1 is involved in epigenetic 
regulatory mechanisms leading to an enhanced  accessibility of the genome to several 
transcription factors implicating its synthesis [134]. The subsequent inhibition of cyclin 
D1 mRNA translation by mTOR inhibitors may suppress the growth of malignant cells, 
a therapy strategy which has been already investigated in mantle cell lymphoma and 
other cancers associated with cyclin D1-overexpression [135]. 
2.5.6 Influences of mTOR on angiogenesis 
One of the most important proteins involved in the stimulation of blood vessel formation 
represents HIF-1α (Hypoxia-Inducible Factor 1α) which is encoded by capped mRNAs 
whose translation is influenced by mTOR-signaling. It positively regulates the 
transcription of the gene for VEGF-A (Vascular Endothelial Growth Factor A), a potent 
angiogenesis stimulating factor. Its overexpression has been associated with 
aggressive disease and poor prognosis in several types of cancer [136-138]. Increased 
expression of HIF1α also showed in many cases a significant correlation with de-
regulated mTOR-related pathways found in different cancers [139]. In normal cells with 
sufficient blood supply and the presence of adequate oxygen level, HIF1α is rapidly 
ubiquitinated and subsequently degraded by proteosomal activity. In contrast, within a   
hypoxic environment, which commonly occurs in the center of tumor nodules, HIF-1α 
translocates to the nucleus and binds to HIF-1β, initiating the transcription of VEGF-A 
and numerous gens involved in anaerobic glycolysis, glucose transport and metastasis. 
Consequently a hypoxic tumor increases its oxygen supply by the formation of new 
blood vessels and ensures its survival through the generation of sufficient energy [140]. 
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Figure 25. mTOR, angiogenesis and 
response to hypoxic stress [115]. 
Inhibition of mTOR activity reduces the 
expression of genes stimulated by HIF1α, 
affecting tumor angiogenesis especially by 
suppressing the proliferation of 
vasculature-associated smooth muscle 
cells which are required for vessel 
maturation [141]. 
2.5.7 mTOR-inhibitors  
Rapamycin (sirolimus) is a macrocyclic 
lactone (Fig.26) produced by the 
bacterium Streptomyces hygroscopicus 
which was discovered for the first time on 
the Easter Island Rapa Nui [142]. In 1975 rapamycin was synthesized as a white water-
insoluble substance and already first evaluations of the National Institute of Health (NIH) 
could demonstrate its cytostatic characteristics. However, further investigations on 
rapamycin focused primarily on immune suppressive properties [143] rather than 
development for cancer therapeutical implementations. Currently, rapamycin is clinically 
used after certain transplantations to prevent heavy immune reactions [144, 145]. Only 
the identification of mTOR as specific target of rapamycin and concerns about novel 
anticancer strategies forced further investigations towards this field. An important step 
for its further development was taken when temsirolimus (CCI-779), a water-soluble 
derivate, was synthesized and offered the systemic application of this new targeted 
compound [146]. In 2007 temsirolimus was approved by the U.S. Food and Drug 
Administration (FDA) [147] . The mode of action of rapamycin and its analogs relay on 
its binding to the cytosolic immunophilin FK-binding protein 12 (FKBP12), forming a 
complex that only binds mTOR and therefore grants its specificity. As described before 
(s. ch. 2.5.2) activated mTOR forms two complexes which maintain different regulatory 
functions, mTROC1 and mTORC2. The latter contains the protein RICTOR 
(Rapamycin-insensitive companion of mTOR), which was originally named based on 
the ineffectiveness of rapamycin to inhibit mTORC2 activity. However, recent studies 
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Figure 26. Comparison between the chemical structures of sirol imus 
(rapamycin) and temsirolimus (CCI-779) [145]. 
have demonstrated that chronic exposure to rapamycin also inhibits the formation of 
new mTORC2. It is believed that pre-existing mTORC2 is not affected but rather 
binding of rapamycin to free mTOR is promoted which results in reduced adherence of 
RICTOR  [148]. 
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3. AIM OF THE STUDY 
Human malignant mesothelioma (HMM) is an aggressive tumor of serosal surface such 
as the pleura and peritoneum with generally poor prognosis. It is strongly associated 
with asbestos exposure and shows a 20 to 50 year latency period. Clinical treatment of 
mesothelioma patients with conventional chemotherapeutics as cisplatin and 
pemetrexed shows poor response. For this reason the development of new therapeutic 
concepts with higher efficiency is urgently needed. Within carcinogenic development, 
pathologic activation of the mTOR (mammalian target of rapamycin) pathway takes a 
central position. This pathway is strongly associated with increased cell proliferation, 
angiogenesis, cell motility and raised survival potential leading to apoptosis resistance. 
Various types of cancer cells show an abnormal level of this molecule including 
malignant mesothelioma cells as existing data confirm [149, 150]. Consequently, the 
targeted inhibition of these oncogenic signals represents a main focus of modern 
cancer therapy. Temsirolimus, an inhibitor of mTOR, is a “targeted compound” with 
widespread antineoplastic effects and may be a promising candidate in the treatment 
of HMM. 
The aim of the here presented study was 
 
1) To gain more insight into the role of mTOR in HMM and determine its 
constitutive activation status in surgical specimens and mesothelioma cell 
models. Further, we investigate for genetic aberrations in HMM cell lines using 
aCGH with the main focus on genes involved in the mTOR pathway. 
2) To investigate the anti-cancer activity and the mode of action of temsirolimus as 
single agent against HMM cell lines. To this end, several analyses regarding 
cytotoxicity, cell proliferation, impact on DNA synthesis, cell cycle distribution as 
well as cell death induction in monolayer and three-dimensional (3-D) cell culture 
systems are performed. 
3) To compare the anti-tumor potential of temsirolimus with cisplatin and 
pemetrexed and to test whether the combination of the targeted compound with 
conventional chemotherapy results in synergistically anti-cancer effects. These 
aspects are investigated in vitro as well as in in vivo xenograft models. 
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4. MATERIALS AND METHODS 
4.1 Cell culture 
All MPM cell lines were maintained in RPMI 1640 or M10 with 10% FCS in a humidified 
atmosphere of 5% CO2 at 37˚C. The list of used cell lines, their histological subtype and 
source are summarized in Table X. The cisplatin-resistant P31res1.2 subline was 
established from the parental P31 by in vitro cisplatin selection to a final concentration 
of 1.2mg/L [151]. Cell lines were authenticated by array comparative genomic 
hybridization (aCGH) in all cases in 2009. The identical origin of the P31parent and 
P31res1.2 were additionally proven by DNA finger printing. 
 
 
Cell line Histologic subtype Growth Medium Source 
P31 epithelioid M10 K. Grankvist 
Umeå University 
P31res1.2 epithelioid M10 K. Grankvist Umeå University 
SPC111 biphasic RPMI 1640 
R. Stahel 
University of 
Zurich 
SPC212 biphasic RPMI 1640 
R. Stahel 
University of 
Zurich 
NCI-H28 epithelioid RPMI 1640 ATCC 
NCI-H2015 epithelioid RPMI 1640 ATCC 
 
Table 5. List of used cel l l ines and their growth medium  
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4.2 Clinical samples 
Formalin-fixed, paraffin-embedded tumor tissue was available from 70 patients 
suffering from histological proofed malignant pleural mesothelioma. All patients 
underwent resection between 01/1993 and 01/2010 at the Medical University of 
Vienna, Department of Thoracic Surgery. The tumor tissue blocks were embedded 
during pathological routine diagnostic work up and coded by identification numbers 
given from the pathologic department during routine investigation. From each tumor 
block, sections were cut at 4 μm. H&E-stained sections were used to confirm the 
presence of invasive carcinoma. Informed consent was obtained from all patients. 
4.3 Drugs 
Temsirolimus was obtained from Wyeth Phamaceuticals Inc., Cambridge, USA, 
cisplatin from Sigma, Saint Louis, USA and pemetrexed from Eli Lilly Pharmaceutical, 
Indiana, USA. For in vitro experiments temsirolimus was dissolved in DMSO at 25ng/μl, 
cisplatin in PMF at 20mM and pemetrexed in 0.9% NaCl at 25mg/ml stock. Before 
application all drugs were further diluted in culture medium. For in vivo experiments 
temsirolimus was diluted in 5% PEG/5% Tween and cisplatin in serum-free culture 
medium. DMSO concentrations were always below 1% in vitro and proven to be 
ineffective at those concentrations in all cases. 
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4.4 Immunohistochemistry 
Background: 
Immunohistochemistry (IHC) is a method to visualize proteins of interest (antigens) 
within tissue samples and cell compartments via specific antibodies. For oncological 
approaches this technique helps to identify and classify tumors obtained from biopsies 
which express certain known antigens. Thus, it is possible to distinguish tumors by 
important parameters, so called “biomarkers” such as growth rate, metastatic activity 
or responsiveness to therapy even when they show a similar morphology. Within basic 
biology research, IHC represents also an important tool to verify proteins of interest and 
to examine the expression status in the investigated tissue. 
The main principle of IHC relays on the affinity of antibodies to their specific epitope 
(antigen) within the tissue (antigen-antibody interaction). To visualize the presence of 
targeted antigens, antibodies are coupled with a detection system that is most 
frequently an enzyme, such as peroxidase, which catalyzes a color-producing reaction 
after adding a dedicated substrate. Alternatively, also fluorophores can be used to 
visualize an antigen-antibody interaction using a immunofluorescence microscope. If 
already the antibody that binds directly its antigen is linked with a detection system, the 
technique is referred to as “direct method” which is quite simple and rapid. However, in 
this case it is not possible to amplify the signal which becomes particularly important 
for a lowly expressed antigen. For this reason a more common used technique 
represents the “indirect method” that involves at least two different antibodies. In the 
first step an unlabeled primary antibody reacts with its antigen and can only be 
visualized after adding a secondary antibody that is conjugated to an enzyme or tagged 
to a fluorophore. The secondary antibody only reacts with the primary antibody which 
features multiple binding sites making this indirect method more sensitive through 
signal amplification. The second step of this procedure involves finally the indirect 
visualization of the targeted protein by different methods depending on the used type 
of detection system. The most common applied immunohistochemical indirect method 
for the analyses of surgical tumor specimen is the Labeled Streptavidin-Biotin method 
(LSAB). It utilizes a biotinylated secondary antibody that links primary antibodies to 
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Figure 27. Comparison of two immunohistochemical methods. (A) The direct 
IHC method involves antigen specif ic ant ibodies (AB) which already feature a 
detection system. Then a dedicated substrate is added to visualize the 
targeted antigen. (B) The Labeled Streptavidin-Biot in method (LSAB) as 
example of the indirect IHC system. In this case an unlabeled primary AB 
binds its specific antigen. Then a secondary biotinylated AB specifical ly binds 
the primary AB. Added streptavidin binds with high aff inity to biotin the 
secondary AB. Final ly adding 3, 3’-Diaminobenzidine (DAB) catalyzes a 
brownish staining visualizing the targeted antigen.               
A B
multiple streptavidin-horseradish peroxidase conjugates due to their high affinity to 
biotin. By adding 3, 3’-Diaminobenzidine (DAB), a brownish staining is catalyzed 
wherever secondary antibodies are attached. This method has become widely used 
since it is able to overcome some of the limitations of earlier fluorescence antibody 
methods especially in commonly formalin-fixed paraffin-embedded tissues samples. 
 
 
Preparation: 
Briefly, tissue sections were deparaffinized and rehydrated. After heating for 10 min in 
10 mmol/L citrate buffer (pH 6.0) in a pressure cooker for epitope retrieval, the tissue 
sections were incubated over night at 4°C with primary antibodies (p-mTOR Ser2448; 
Cell Signaling; Ki67, Dako; dilutions 1:100). Antibody binding was detected by means 
of the UltraVision LP detection system according to the manufacturer's 
recommendations (Lab Vision Corporation). Color development was done by 3,3′-
diaminobenzidine and counterstaining by hematoxylin. p-mTOR immunostaining was 
independently evaluated by two authors (Amir Mohamed, Ulrike Setinek) in at least five 
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representative areas per section. Interpretation of the results was limited to proven 
tumor tissue and only cytoplasmic staining was considered positive. Staining intensity 
was scored as strong=3, moderate=2, weak=1. Intensity scores were multiplied by the 
respective percentages of cells and divided by 3, resulting in an H-score from 0-100. 
The results were correlated with clinical/histological data using the SPSS 17 software 
package.  
4.5 Genome analyses 
4.5.1 Array comparative genomic hybridization 
Background:  
Malignant cell transformation is guided by an increasing number of mutations in genes 
controlling cell growth and cell death as well as genomic stability. Array comparative 
genomic hybridization (aCGH) is a powerful technique to detect genome-wide gains 
and losses of genes caused by chromosomal aberrations in tumor cells. The method is 
based on co-hybridization (1:1 ratio) of fluorescent-labeled tumor (green) and reference 
DNA (red) onto an array of immobilized DNA oligonucleotide fragments (represent main 
sequences of the human genome) printed on a glass slide. After scanning the slide, 
software calculation allows to determine the ratio between both fractions, giving under-
represented hybridization levels of tumor DNA as gene losses and dominant signal 
intensities from individual spots as gene dose gains compared to the reference 
fluorescence levels. Array CGH represents a further development of conventional CGH 
which relies on the same principals but in this case hybridization takes place on whole 
metaphase chromosomes limiting detection resolution for aberrant DNA changes to 
that of light microscopy (~5MB). In contrast, aCGH allows zooming with an 
intermediate (44K) or high resolution (244k) array into chromosomal regions at the level 
of single genes.  
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Preparation: 
aCGH was performed using 4x44K whole genome oligonucleotide-based arrays for 
humans (Agilent). Labeling and hybridization procedures were performed according to 
the instructions provided by Agilent. Shortly, reference DNA and test DNA were 
digested with AluI and RsaI (both Promega), then differentially labeled by random 
priming with Cyanine 3- and Cyanine 5-dUTP (Perkin-Elmer). Human genomic male 
DNA (Promega) was used as reference DNA. After purification with Microcon YM-30 
filter units (Millipore) the two labeled products together with Blocking Agens, 
Hybridization Buffer (both included in the Oligo aCGH/Chip-on-Chip Hybridization Kit, 
Agilent), and human cot-DNA (Roche) were combined and hybridized onto the 4x44K 
oligonucleotide arrays for humans (Agilent). Hybridization was carried out for 48h at 
65°C in a hybridization oven. Afterwards, slides were washed according to the protocol 
and scanned with a G2505B Micro Array Scanner (Agilent). Feature extraction and data 
analysis were carried out using the Feature Extraction and DNA Analytics software, 
respectively. 
Figure 28. I l lustration of the main steps involved in array comparat ive genomic 
hybridizat ion (aCGH) 
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4.6 Cell proliferation and cell vitality assays 
4.6.1 Cytotoxicity assays 
Background: 
A common method to determine indirectly the cytotoxicity of different drugs as single 
agent or in combination against cell lines in vitro represents the MTT-assay. This 
colorimetric assay is based on the enzymatic reduction of 3-(4,5-Dimethylthiazol-2-yl)-
2,5-diphenyl-tetrazolium bromide) (MTT) to formazan giving a deep orange color. 
Because this reduction requires active and functional mitochondrial reductase 
enzymes, only viable cells will give an orange coloration while dead cells remain 
uncolored.  The staining intensity is then determined by absorbance measurement at a 
wavelength of 450 and 620 nm in a spectrophotometer. Finally the comparison 
between coloration of the untreated control and treated cells reveals a ratio that 
indicates the cytotoxic or cytostatic effects of drugs.  
Preparation: 
MM cells were seeded in 96-well microtiter plates at a density of 2x103 cells in 100μl 
growth medium per well and allowed to recover for 24 hours. Dissolved drugs were 
diluted in growth medium and added to the cells in different concentration ranges for 
24h to 72h at 37°C in humidified atmosphere and 5% CO2. Subsequently the 
proportion of viable cells was determined by MTT assay following the manufacturer’s 
procedure (EZ4U, Biomedica, Vienna, Austria). After incubation for 1-4 hours, 
depending on the metabolic capacity of the different cell lines, plates were gently 
Figure 29. MTT is reduced in formazan by a mitochondrial reductase 
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shaken before absorbance measurement at 450 nm or 620 nm as reference 
respectively. Cytotoxicity was expressed as IC50 values (half maximal inhibitory 
concentration) and calculated by the software GraphPad Prism 5.0 from dose-
response curves. 
4.6.2 Clonogenic assays 
Background: 
To study long-term effects of specific agents on the 
survival and proliferation of single tumor cells, their 
capacity to form colonies after drug exposure can be 
analyzed by clonogenic assays. Therefor single cells 
are plated at a very low density in drug containing 
medium and the formation of colonies is evaluated 
subsequently. For better visualization, cells can be 
stained with crystal violet (hexamethyl pararosaniline 
chloride) which has the ability to intercalate DNA. 
Preparation: 
Cells were seeded into 6-well plates at densities of 2x103 to 5x103 cells/well 24h before 
treatment. Dissolved drugs were diluted in growth medium and added to the cells in 
different concentration ranges. After 7 days drug containing medium was removed, 
cells were washed three times with PBS and fixed for 10 minutes with ice-cold 
methanol at 4°C. Subsequently the cells were stained with crystal violet (stock: 10% 
crystal violet in ethanol; diluted 1:1000 in PBS) for ~ 5 minutes and again washed with 
PBS. Finally the clones were dried at room temperature (RT) and evaluated by 
microscopical counting the clones. 
 
Recipes: 
10x PBS: 
95 g 0.53 M Na2HPO4 x 2 H2O 
32 g 0.23 M NaH2PO4 x H2O; Σ 1 l ddH2O  
Figure 30.  Chemical structure 
of hexamethyl pararosanil ine 
chloride 
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Figure 31. (A) Hoechst 33258 
intercalated into DNA of cells 
and its chemical structure. (B) 
propidium iodide (PI).   
4.6.3 Hoechst 33258-PI staining 
Background: 
Hoechst 33258 is a fluorescent DNA intercalating 
nuclear dye that can be used to observe different 
states of the nucleus during apoptosis, necrosis or 
cell cycle by visualizing apoptotic bodies and 
condensed chromosomes during mitosis. Due to its 
ability to pass through intact membranes of living or 
fixed cells, it easily intercalates into double stranded 
DNA and produces a bright blue fluorescence 
when excited with ultraviolet light at 465nm 
wavelength. In cell vitality assays, the Hoechst dye 
is commonly combined with propidium iodide (PI), 
another DNA-intercalating stain that can be excited 
with U.V. at 488nm giving red fluorescence. In 
contrast to Hoechst 33258, PI is membrane 
impermeable and generally excluded from viable 
cells. Hence it represents a factual verification of 
dead cells (necrotic cells and late apoptosis). 
Preparation: 
Cells were plated in 6-well plates at a density of 2x105 cells in 2ml growth medium per 
well and allowed to recover for 24 hours. Dissolved drugs were diluted in growth 
medium and added to the cells in different concentration ranges. After drug exposure, 
cells were trypsinized, collected, washed once with PBS, centrifuged for 5 minutes at 
1100 rpm and resuspended in 300 μl PBS. Cytospins (Shandon Cytospin 3 Centrifuge 
Cell Preparation System) were performed with three slides for each sample which had 
been aliquoted (50-75μl) before. Then the cells on the slides were fixed using a 1:1 
methanol-aceton solution for ~10 minutes and stained with DAPI containing antifade 
solution (Vector Laboratories, Inc., Burlingame, CA). Nuclear morphology was 
examined using a Leica DMRXA fluorescence microscope (Leica Microscopy and 
A
B
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System, Wetzlar, Germany) equipped with appropriate epifluorescence filters and a 
COHU charge-coupled device camera. 
4.6.4 TUNEL assay 
Background: 
Terminal transferase dUTP nick end labeling (TUNEL) is a method to detect DNA strand 
breaks in apoptotic cells. During to the late stage of apoptosis nucleic DNA is 
fragmented by endonucleases ensuring the programmed cell death. Hence, a multitude 
of 3’-hydroxyl DNA termini accrues within the nuclei which can be labeled using 
terminal deoxynucleotidyl transferase (TdT) and commonly fluorescent-tagged 
deoxyuridine triphosphate nucleotides (dUTP). TdT catalyzes the template-independent 
addition of dUTPs to the 3’-OH ends of nicked DNA. In this study we used standard 
immunohistochemical techniques to visualize the labeled DNA breaks of MM xenograft 
tissue. 
Preparation: 
In this study TUNEL assay was used to visualize drug induced cell death in harvested 
xenograft tumors. Therefore tumor samples were primarily fixed in formalin and 
embedded in paraffin according to standard protocols. Then TUNEL assay was 
performed using the “In Situ Cell Death Detection Kit, Fluorescein” obtained from 
Roche Diagnostics GmbH, Germany. First paraffin-embedded tissue samples were 
dewaxed and rehydrated. After washing, tumor slides were incubated with TUNEL 
reaction mixture (enzyme solution + labeling solution) for 60 min at 37°C. Finally slides 
were again washed and analyzed by fluorescence microscopy.   
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Figure 32. Deoxythymidin 
4.6.5 3H-thymidine incorporation assays 
Deoxythymidin (dT), or short thymidine, is a 2’-
deoxynucleosid composed of the pyrimidine 
nucleobase thymine and the pentose D-deoxyribose. 
When phosphorylated, thymidine represents a 
component of the DNA (deoxyribonucleic acid) and 
pairs with deoxyadenosine to form a double helix. In 
contrast to other deoxynucleosides which also arise as 
nucleosides in the RNA (ribonucleic acid), thymidine is 
found only in DNA. Based on this fact, the 
quantification of the thymidine amount within cells 
represents an excellent indicator to draw conclusions from DNA synthesis and thus 
allows to determine whether a cell population is proliferating (enhanced thymidine level 
during S-phase) or dying (reduced thymidine level during cell lysis). During cell 
proliferation assays radioactive labeled thymidine (tritiated thymidine; 3H-thymidine) is 
supplied and can be detected using scintillator solution via a liquid scintillation counter 
measuring the fluorescence level of a transparent crystal which fluoresces through 
radioactive radiation. 
Preparation: 
Cells were seeded in 96-well microtiter plates at a density of 2x104 cells/well 24 h prior 
drug treatment. After 24 h exposure time the medium was removed and 100μl of a 
2nM solution of 3H-thymidin (specific activity: 25ci/mM; GE Healthcare) was added to 
each well. Following incubation for 2h at 37°C cells were washed twice with ice-cold 
PBS, lysed in 100μl lysis-buffer and transferred into scintillator tubes. The 96-wells 
were washed again with 100μl PBS and also transferred to the cell lysates in the 
scintillator tubes. After addition of 5ml liquid scintillator (KFORO Laboratories), the 
samples were mixed by turning upside down and finally measured using a liquid 
scintillation counter (Tri-Carb 1900TR, Packard). 
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Recipes: 
Lysis buffer 3H-thymidine incorporation: 
10 mM Tris-HCl, pH= 7.8 
1% SDS 
Σ 1 l ddH2O 
4.6.6 HMM cell spheroid growth assays 
(performed in collaboration with B. Hegedus) 
Background: 
Multicellular tumor spheroids are globular aggregates formed by several thousand 
malignant cells and can be used as three-dimensional (3-D) cell culture systems for a 
large range of molecular analysis. Compared to conventional cell culture experiments, 
spheroid based assays more closely resemble the in vivo situation with regard to cell 
shape and cellular environment. These characteristics can determine gene expression 
and the biological behavior of cells as well as an advanced degree of differentiation. 
Several studies have emphasized the different behavior of cells in 3-D cell cultures 
compared to monolayers. For example it was shown that isolated and conventionally 
recultured tumor cells from drug resistant in vivo xenograft lost their therapy resistance 
in vitro, while grown as multicellular spheroids maintained a comparable insensitivity to 
the applied agent as in vivo [152, 153]. This phenomenon is referred to as contact 
effect which underlies a multitude of mechanisms such as an improved accessibility of 
repair enzymes to their substrates. Further the specific nuclear shape and DNA packing 
of spheroids may also contribute to a more efficient DNA-repair resulting in an 
enhanced drug resistance especially to DNA intercalating agents. 
Besides the shape-associated characteristics of 3-D cell cultures, spherical colonies 
established from a multitude of different malignancies showed significant overlap with 
the genetic programs of progenitor/stem cells after transcriptional profiling [154]. Thus, 
it is believed that spheroids consist of a distinct subpopulation of cancer stem cells or 
tumor initiating cells that feature self-renewal capability and are responsible for the 
generation of more differentiated progeny cells. These characteristics were originally 
demonstrated in neural cells and cell lines derived from primary glioblastomas and 
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successively also verified for other tumors such as melanoma, ovarian and mamma 
carcinomas [155-157]. However, further studies revealed that spheroid-formation 
capacity is a property that strongly differs between various types of tumors and that 
some spheroids lack of significant cancer stem cell markers [9]. Although it is unclear 
whether the spheroid assay can be generally associated with cancer stem cells due to 
differing data and arguments, it has formed an important basis to study tumor-initiating 
cancer stem cells in a variety of solid tumors. Considering the possible differences 
between monolayer and 3-D cell culture based analysis, multicellular tumor spheroid in 
vitro models represent an alternative strategy for enhanced studies on tumor cell 
response to therapy and self-renewal capacity according to the cancer stem cell 
hypothesis (s. chapter. 2.2). 
Several methods are applied to induce the formation of a three-dimensional structure 
by single cells. In this study we used microtiter plates with super-hydrophilic non-
adherent surfaces which physically force the cells to generate aggregates.  
Preparation: 
To establish spheroid cultures from HMM cell lines, 5x103 cells were seeded in triplicate 
in DMEM/Ham’s F-12 medium (PAA Laboratories, Austria) supplemented with 20ng/ml 
basic fibroblast growth factor (bFGF, Eubio, Austria), 20ng/ml epidermal growth factor 
(EGF; Sigma) and 2% B27 supplement (PAA Laboratories, Austria) in ultra-low 
attachment 24-well plates (Corning, NY). Temsirolimus was added at 100ng/ml. 96 
hours after plating all spheroids of each well were photographed. In order to exclude 
small cell clumps from the analysis, only the spheres with a diameter over 100μm were 
counted and their diameter measured on the digital photographs using Image-J 
software. In order to assess the self-renewal capacity of spheroid-derived cells, the 
spheres were treated for 10 min with trypsin (0.1%) and EDTA (0.01%). Cells were 
resuspended in DMEM/FBS medium and washed once in serum-free medium and 
passed through 70 μm filter (BD Biosciences, Bedford, MA). After centrifugation the 
single cell suspension was re-plated under the aforementioned conditions. 
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4.7 Cell cycle analyses 
4.7.1 Flow cytometry 
Background: 
The cell cycle is referred to as the process of cell reproduction by performing an orderly 
sequence of events that involves the duplication of its contents and finally leads to the 
division into two daughter cells by mitosis. After division each cell starts the cell cycle in 
the interphase, a stage which can be subdivided into G1- (duplication of cellular 
contents), S- (synthesis of DNA) and G2-phase (chromosome check and repair). If the 
genome has been properly duplicated and putative failures have been corrected the 
cell continues with mitosis closing the circuit. Multicellular organisms also contain cells 
which no longer divide and remain in a quiescent state, called the G0-phase. Such 
terminally differentiated cells are e.g. neurons or heart muscle cells. In contrast 
immortalized tumor cell cultures in vitro normally do not fall in quiescence and continue 
unlimited proliferation. 
When testing the effects of drugs 
on tumor cells, the examination of 
cell cycle changes can give a 
deeper insight into the mode of 
action of these agents. Cell cycle 
analyses are commonly performed 
using flow cytometry, a technique 
that provides the possibility to 
count fluorescent antibody- or dye-
labeled cells and examine their DNA 
content which changes during 
phases of cell cycle. A frequently 
used staining is propidium iodide 
(PI) which intercalates the major 
groove of double-stranded DNA 
Figure 33. A funct ional i l lustrat ion of f low 
cytometry. 
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and is able to fluorescence after excitation with 488nm. Hence, measuring the 
fluorescence level of drug-treated, PI-labeled cells depicts their proportional DNA 
amount, which gives an indication of whether the cells may have arrested in a certain 
cell cycle phase (Fig.34). Therefore stained cells are suspended in a stream fluid and 
solitary pass a laser beam within an electronic detection module that measures the 
excitation of every single cell (Fig.33). 
 
 
Preparation: 
Cells were seeded in 6-well plates at a density of 5x105 cells in 2ml growth medium per 
well over night prior 24h drug treatment. Further cells were trypsinized and washed 
once with FACS-PBS. The cell pellets were resuspended in 100 μl 0.9% NaCl and 
dropped slowly into 70% ice-cold ethanol. To prepare cells for PI staining, they were 
treated with NaCl and ethanol permeabilizing the cell membranes to provide the 
diffusion of PI into the cell. After at least 1h incubation at -20˚C, cells were centrifuged 
again 1 minute at 8000 rpm and resuspended in 1 ml FACS-PBS. To prevent a 
possible intercalation of PI into RNA, 0.79 Kunitz units/ml RNAse A were added and 
samples were incubated at 37˚C for 30 minutes. Then cells were filtrated into FACS 
tubes, stained with 1 mg/ml of PI for another 30 minutes at 4˚C, and fluorescence was 
Figure 34. (A) Schematic cel l cycle overview highlight ing genomic ploidy. (B) FACS 
diagram i l lustrating several dif ferent peaks indicat ing the amount of cel ls in the 
specif ic cel l phase   
A B 
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measured by flow cytometry (FACS Calibur – Becton Dickinson, Palo Alto, CA) using 
Cell Quest Pro software.  
 
Recipes: 
FACS-PBS:  
11.5 g Na2PO4 x 2 H2O  
2 g KH2PO4  
2 g KCl  
80 g NaCl  
Σ 1 l ddH2O 
  
4.8 Protein analysis 
4.8.1 Protein extraction 
Preparation: 
Cells were seeded as appropriate either in 6-well plates or 10cm plates at a density of 
3x105/well and 2x106/plate, respectively, prior drug treatments. After 24h, 48h or 72h 
exposure time, the cells were collected by scraping into the medium and centrifuged at 
1200 rpm for 5min. Next the cell pellet was washed once with PBS and then lysed with 
30-50ml lysis buffer on ice for 10min. For enhanced destruction of cell membranes, the 
samples were treated in a sonicator for 3min and then centrifuged at 14.000 rpm for 
15min at 4°C. After discarding the pellet containing nuclei and dense cell analyses, 
protein concentrations of collected supernatants were determined by using Micro 
BCATM Protein Assay Reagent Kit (Pierce Biotechnology, Rockford, USA). All protein 
lysates were stored in aliquots at -80°C. 
Recipes: 
Lysis buffer: 
500 μl lysis buffer (s. ch. 4.6.5); 0.5% Triton X-100  
10 μl/ml phenylmethanesulphonylfluoride (PMSF) –serine protease inhibitor, Roche-  
25 μl/ml Complete (protease inhibitor cocktail tablets, Roche) 
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4.8.2 Western blot analyses 
Background: 
The investigation of protein levels generally plays an important role in life science and 
was used in this study to gain more insight into molecular changes of cells after drug 
treatment. Western blotting, the standard method for detecting specific proteins in a 
prepared cell lysate, is an immunochemical technique that allows to visualize targeted 
proteins via specific antibodies. As a first step the proteins in a given heterogenic 
protein lysate are separated by electric current using SDS-PAGE (sodium dodecyl 
sulfate polyacrylamide gel electrophoresis) consisting of two different polyacrylamide 
gels, a collecting and a separating one. The protein samples are loaded into the 
collecting gel where components become stacked into a very thin, sharp band prior 
entering the separating gel in which the proteins are fractionated by size. Both gels 
contain denaturing SDS buffer, an anionic detergent that binds proteins and unfolds 
them. Further SDS also masks the native charge of proteins by giving them a near 
uniform negative charge along their length. This results in an equal charge to mass ratio 
which is a necessary property for the unique migration of all different proteins in an 
installed electric filed towards the plus pole. An essential precondition for this 
movement is also the uniform shape of all proteins which is provided by the denaturing 
characteristics of SDS that destroys secondary and tertiary structures leaving only 
unfolded peptide bonds between amino acids. 
  
Figure 35.  SDS PAGE: At the beginning protein samples are loaded onto a chloride-
containing gel which is situated in a tank with electrode-buffer that contains 
zwitterionic glycine. Due to electr ic current, the chloride ions start to migrate in front of 
the glycine ions which entered the gel. In the col lecting gel the proteins form an 
intermediate layer between the two different ions. Finally, in the separating gel the 
proteins become fractionated by size.     
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In this study we used a discontinuous buffer system that employs different buffers for 
the gels (collecting gel: Tris-HCl buffer- pH6.8; separating gel: Tris-HCl buffer – ph8.8) 
and the tank (electrode buffer: Tris-glycine buffer – pH8.8). During electrophoresis 
glycine ions, supplied by the electrode buffer, enter the collecting gel that slows down 
their mobility and leads to a zwitterionic form of the molecules at pH6.8. In contrast the 
chloride ions from the gel are smaller and negatively charged causing their much higher 
mobility and formation of a leading front. Due to the resulting voltage drop between 
glycine and chloride ions, the intermediate proteins become compressed into very thin 
layers creating the focused narrow zone at the top of the separating gel. Here the pH 
abruptly increases and leads to the ionization of glycine resulting into a faster 
movement of these now negatively charged molecules. Due to the higher acrylamide 
concentration in the separating gel, the smaller pores of the gel matrix decrease the 
mobility of proteins which now become separated by size. 
Since the final gel is hard to conserve and is not accessible for antibody detection, the 
separated proteins have to be transferred on to a solid membrane. In this study we 
applied a polyvinylidene fluoride (PVDF) transfer membrane and the semi-dry blotting 
technique. This is an electrophoretic method that uses an electric field which forces the 
negatively charged proteins in the gel to migrate on to the membrane where they are 
bound manly due to hydrophobic interactions. Two stacks of filter paper, one at the top 
of the gel soaked with a cathode buffer, and another below the membrane soaked with 
an anode buffer, act as ion-reservoirs and maintain the electrical potential between the 
poles. By adding methanol to the anode buffer SDS is removed from the proteins 
providing their more efficient binding to the membrane. 
To eliminate nonspecific background the membrane with bound proteins has to be 
further processed after blotting. First it is washed with TBST (tris-buffered saline with 
Tween) which removes all unbound components. Then the membrane is placed in a 
bovine serum albumin (BSA)- and non-fat dry milk -containing solution which provides 
an overage of proteins that attach all remaining polypeptide-free areas on the 
membrane. Consequently, antibodies obtain no possibility to unspecifically bind the 
membrane. After washing and blocking, finally the detection and visualization of 
targeted proteins is performed. Therefore the membrane is incubated with a solution 
www nationaldiagnostics com
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containing a primary antibody that is directed against monoclonal or several polyclonal 
epitopes at the protein of interest. Then a reporter enzyme (commonly horse radish 
peroxidase)-labeled secondary antibody that binds the species-specific region of the 
first antibody is added. In the presence of a chemiluminescent agent which is cleaved 
by the reporter enzyme, the antigen-antibody complex starts to produce luminescence. 
For the detection, a sensitive photographic film is placed on the membrane and the 
luminescence signal blackens the film at the specific protein spot. 
Preparation: 
SDS-PAGE (sodium dodecyl sulphate polyacrylamide gel electrophoresis) was 
performed using 10% separating gel and 4.5% collecting gel. Electrophoresis was 
conducted with 90V till protein bands reached the end of the western blot chamber. 
The gels have been blotted using Trans-Blot SD (Biorad) onto a polyvinylidene 
difluoride membrane with 0.08 mA for 45 minutes. After blocking with milk solution 
(0.5% BSA, 1% milk powder) for at least 1 hour, the membranes were incubated with 
the primary antibodies (1:1000 dilution with 3% BSA) against mTOR, pmTOR, S6, pS6, 
S6K, pS6K, 4EBP1, p4EBP1 and β-Actin (Santa Cruz; Cell Signaling) at 4°C 
overnight. Membranes were washed three times with TBST and incubated for 1 hour 
with HRP-coupled anti-rabbit antibody (1:10000 dilution in 1% BSA, Santa Cruz 
Biotechnologies). The membranes were washed again three times with TBST for 10min 
and the proteins were detected using Santa Cruz Biotechnology Detection Kit following 
the instruction of the manufacture. 
Figure 36. I l lustrated 
steps during the western 
blot procedure  
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Receipts:  
Tris-HCl 1.5 M, pH= 8.8:         Tris-HCL 0.5 M, pH= 6.8  
18.2 g Tris             3 g Tris  
Σ 100 ml ddH2O, pH= 8.8         Σ 50 ml ddH2O, pH= 6.8 
  
Lysis buffer:             4x Sample loading buffer:  
50 mM Tris-HCl, pH= 7.6        4 ml 10% Glycine  
300 mM NaCl             2 ml 2-Mercaptoethanol  
0.5% Triton X-100          0.92 g SDS  
Σ 500 ml ddH2O           2.5 ml 1 M Tris-HCl (pH= 6.8)  
               Σ 10 ml ddH2O  
 
10x TBS:            1x TBST:  
120 g Tris            100 ml 10xTBS  
90 g NaCl             900 ml ddH2O  
Σ 1 l ddH2O, pH= 7.6          1 ml Tween 20 ( Bio-Rad) 
  
10x Laemmli-Electrophoresis buffer:    Bjerrumbuffer with SDS:  
30 g Tris             5.82 g Tris  
144 g Glycine             2.93 g Glycine  
10 g SDS             0.375 g SDS  
Σ 1 l ddH2O             Σ 1 l ddH2O  
 
Bjerrumbuffer with Methanol:       SDS-PAGE – 4.5% Collecting gel:  
5.82 g Tris             1.56 ml ddH2O  
2.93 g Glycine             0.281 ml Acrylamid  
200 ml Methanol          0.625 ml 0.5 M Tris-HCl, pH= 6.8  
Σ 1 l ddH2O             25 μl 20% SDS  
               12.5 μl 10% APS  
 2.5 μl TEMED  
SDS-PAGE – 10% Separating gel:  
3.65 ml ddH2O  
1.875 ml Acrylamid  
1.875 ml 1.5 M Tris-HCl, pH= 8.8  
75 μl 20% SDS  
5 μl 10% APS  
5 μl TEMED 
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4.9 In vivo xenograft models 
Background: 
In cancer research the term xenograft transplantation referres to the transplantation of 
living malignant cells from one species to another. Generally it has become an 
indispensable in vivo method in tumor biology research and the screening of 
investigative anticancer drugs. In this study we used severe combined 
immunodeficiency (SCID) mice as hosts for HMM cell transplants to investigate the 
tumor reducing effects of temsirolimus and cisplatin on a mammalian system. 
Due to a recessive mutation on chromosome 16 the humoral 
and cellular immune system of SCID mice fails to mature. 
Responsible for this immunodeficiency is the inactive catalytic 
subunit of DNA-PK (DNA-dependent protein kinase), an 
enzyme required for the non-homologous end joining (NHEJ) of 
DNA. Besides the repair of double-strand breaks, NHEJ is 
utilized for V(D)J recombination (Variable, Diverse, and Joining), 
a mechanism that nearly randomly combines and joins different genes resulting in a 
large variability of encoded proteins that match antigens from diverse pathogens and 
dysfunctional cells. Consequently SCID mice obtain an impaired ability to produce main 
players of the adaptive immune system such as B or T lymphocytes as well as to 
activate some components of the complement system. For this reason SCID mice 
cannot efficiently fight infections or reject tumor cell transplants what makes them ideal 
model organisms. 
Preparation: 
All procedures involving animals and their care were approved by the Ethic Review 
Board and performed following FELASA guidelines. 1x106 SPC 111 or P31 cells were 
injected in 200 μl serum free medium i.p. into female 5- to 7-week-old severe 
combined immunodeficiency (SCID) mice (in total N=80). Two weeks after inoculation, 
mice were assigned into treatment groups, each consisting of 5 or 10 mice: 1) treated 
with solvent; 2) temsirolimus (10 mg/kg) every day x 5 for two cycles with two days off; 
Fig. 37: SCID mouse
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3) cisplatin (1 mg/kg) once a week for two weeks; combined temsirolimus and cisplatin 
as aforementioned. Performance status and body weight were checked every second 
day. The first experiment was terminated after 38 days from transplantation when the 
first animal had to be sacrificed due to weight loss. To establish impact on survival, in 
another experiment all mice were kept up to individual tumor progression with weight 
loss and/or ascites development. Tumors i.p. were harvested, weighted and processed 
for histological investigations by routine methods. 
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Figure 38.  mTOR phosphorylation in HMM.(A-C) Representative examples of human 
paraff in-embedded HMM surgical specimens of different histology immunostained for 
phosphorylated mTOR (brown) and counterstained with hematoxyl in (nuclei in blue) (A, 
epitheloid; B, biphasic; C, sarcomatoid).  
5. RESULTS 
5.1 Determination of constitutive mTOR activity 
5.1.1 mTOR - phosphorylation status of MPM surgical specimens 
Out of the 70 mesothelioma specimens analyzed, 43 (61.4%) exhibited epithelioid, 19 
(27.1%) biphasic type and 4 (5.7%) sarcomatoid histology. Additionally, four patients 
with pseudomesotheliomatous adenocarcinomas were investigated in this study (5.7%). 
Fig. X shows expression of phosphorylated mTOR (p-mTOR) in representative cases of 
the different MPM histological subtypes detected by immunohistochemistry. Strong 
immunoreactivity was found predominantly in the epithelioid type tumors (Fig. 38A), 
while sarcomatoid cases were widely p-mTOR negative (Fig. 38C). A comparable 
restriction of p-mTOR immunoreactivity to the epithelioid histology was observed in the 
biphasic tumors (Fig. 38B). Quantitative evaluation by a scoring system confirmed a 
strong phosphorylation of mTOR in mesotheliomas harboring epithelioid histology 
compared to the sarcomatoid type (Fig. 39A). Interestingly, p-mTOR levels were 
particularly high in early-stage disease and tended to moderately decline in late-stage 
HMM (Fig. 39B). Overall patient survival did not correlate significantly with p-mTOR 
staining intensity but tended to be higher in p-mTOR-positive cases (Cox Regression: 
p=0.177) (Fig. 39C). This is not surprising considering the generally strong 
overexpression of p-mTOR in the epithelial subtype and in early-stage disease, both 
characterized by better prognosis [158, 159]. 
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Figure 39.  (A-C) Evaluat ion of 70 patients was performed by H-score as described 
under Material and Methods. Hyper-phosphorylation of mTOR was predominantly 
detected (A) in tumors with epitheloid different iation (mean staining score: 55±30 
[epitheloid] vs. 2±3 [sarcomatoid]; p < 0.0001; unpaired t-test) and (B) in early 
stage epitheloid MPM (mean staining score: 66±27 [epitheloid early] vs. 46±31 
[epitheloid late stage]; unpaired t test, p=0.031; not signif icant for all  other early 
vs. late stage subgroup analyzes). (C) Kaplan-Meier curve shows cumulative 
survival of al l pat ients grouped in relation to p-mTOR staining intensity [H-score p-
mTOR ≤ 50 (dashed l ine); H-score p-mTOR ≥ 50 (cont inuous l ine);]. Overall pat ient 
survival did not correlate signif icant ly with p-mTOR staining intensity (Cox 
Regression: p=0.177).      
A
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5.1.2 The mTOR-pathway is activated in MPM cell lines 
To determine if MPM cell cultures in vitro retain the observed activation of mTOR in 
MPM tumor specimens, five MPM cell models (SPC111, SPC212, NCI-H28, NCI-
H2052, P31) and a cisplatin resistant subline of the latter cell line (P31res1.2) were 
investigated for activation of several mTOR pathway mediators by immunoblot (Fig.X). 
Generally, all investigated mesothelioma cell lines exhibited strong phosphorylation of 
mTOR corresponding to intense activation of the downstream effectors p70S6K, S6, 
and 4EBP1. mTOR activation was also present in two cell lines derived from biphasic 
mesothelioma (SPC111, SPC212) indicating that the in vitro cell cultures predominantly 
reflect the epitheloid histology of the original tumor. In the cisplatin-resistant subline of 
P31, phosphorylation of all investigated mTOR pathway mediators was equal or tended 
to be slightly reduced as compared to the parental cell line (Fig. 40). 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 40. Phosphorylat ion of mTOR and several downstream effectors as 
indicated in the investigated HMM cell l ines by immunoblot. 
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5.2 Comparison of standard chemotherapy and temsirolimus  
5.2.1 Cisplatin as single agent against MPM cell lines 
MTT proliferation assay of the investigated MPM cell models treated with cisplatin at 
concentrations from 0.5μM to 10μM for 72h resulted in hyper-sensitive to highly 
resistant effects. This was demonstrated by a broad variation of the half maximal 
inhibitory concentration (IC50) as shown in Figure 41. The IC50 value of the cisplatin-
resistant sub-line p31res1.2 predictably could not be calculated in this setting and was 
higher than the maximum concentration of 10μM. A comparable minor response to 
cisplatin was also observed in NCI-H28 (IC50 > 10μM), indicating an intrinsic cisplatin 
resistance.  Including SPC212, with a relatively high IC50 of 7.2μM, three of six cell lines 
were rather chemotherapy-resistant compared to the others in this analysis. 
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Cell line IC50 values 
SPC111 0.78μM 
SPC212 7.2μM 
NCI-H28 > 10μM 
NCI-H2052 3.3μM 
P31parental 3.9μM 
P31res1.2 > 10μM 
Figure 41. Cisplatin-IC50 values (upper panel) and changes in viabi l ity after 72h 
cont inuous drug exposure ( lower panel) were measured by MTT assay. Data 
are given normalized to the untreated controls.  
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5.2.2 Pemetrexed as single agent against MPM cell lines 
All MPM cell models were treated with pemetrexed at concentrations from 50μM to 
200μM for 72h within a MTT proliferation assay (Fig. 42) that demonstrated strong 
deviating results. The cell lines SPC212, NCI-H28 and P31parental showed no 
significant changes in cell viability and a stabilized cell number even at higher 
concentrations. With regard to SPC111 pemetrexed obtained moderate growth 
inhibitory effects but also in this case it was not possible to define an IC50 value. The 
number of viable cells was significantly reduced only in NCI-H2052 and P31res1.2 with 
IC50 values already beyond the minimal dose. Interestingly those cell lines which 
obtained nearly no response to pemetrexed also showed high resistance to cisplatin 
(compare Fig. 41). This fact is highlighted by the cell models P31parental and 
P31res1.2, indicating a clear association between acquired cisplatin resistance and an 
arising insensitivity to pemetrexed.  
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Cell line IC50 values 
SPC111 > 200μM 
SPC212 > 200μM 
NCI-H28 > 200μM 
NCI-H2052 20μM 
P31parental 40μM 
P31res1.2 > 200μM 
Figure 42.  Pemetrexed-IC5 0 values (upper panel) and changes in viabi l ity after 
72h cont inuous drug exposure ( lower panel) were measured by MTT assay. Data 
are given normalized to the untreated controls. 
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5.2.3 Temsirolimus as single agent against HMM cell lines 
Based on the strong constitutive activation of mTOR in vitro, we set out to investigate 
the quality of this oncogenic molecule as a therapeutic target in HMM. The applied cell 
lines were treated with temsirolimus at concentrations from 1 to 250ng/ml for 72h within 
a MTT proliferation assay (Fig. 43) and resulted in two groups, with one more sensitive 
than the other.  Two of six cell models showed high sensitivity to temsirolimus already at 
concentrations below 10ng/ml (SPC212, IC50 8.9; p31res1.2, IC50 9.8). In this 
application schedule the other cell lines (NCI-H28, SPC111, p31parental) led to a 
moderate to distinct but in all cases significant reduction of viable HMM cells. However, 
this assay obviously displayed that the cell lines with high resistance to cisplatin (NCI-
H58, SPC212, p31res.1.2; compare chap. 5.2.1) as shown previously, were the most 
sensitive to temsirolimus. 
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Cell line IC50 values 
SPC111 > max dose 
SPC212 8.9ng/ml 
NCI-H28 > max dose 
NCI-H2052 > max dose 
P31parental > max dose 
P31res1.2 9.8ng/ml 
Figure 43.  Temsirol imus-IC5 0 values (upper panel) and changes in viabi l ity after 
72h continuous drug exposure ( lower panel) were measured by MTT assay. 
Data are given normalized to the untreated controls. 
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5.3 Investigation into the mode of action of temsirolimus 
5.3.1 Analyses of genetic aberrations in MPM cell models 
A main characteristic of cancer cells represents their genomic instability causing 
chromosomal aberrations including gains and losses of a multitude of different genes. 
Gene dose can play an important role in aberrant cellular signaling and may lead to 
pathway dysfunction that seriously contributes to the malignant progress and can 
become indispensable for continuous tumor growth. The distinct dependence of tumors 
on specific pathways reflects one of many determinants responsible for individual 
responsiveness to certain therapeutic agents of malignant cells even within the same 
type of cancer. Because this factor represents a possible source of the diverse 
response characteristics to temsirolimus, we performed aCGH analyses of the 
investigated cell lines to detect potential alterations of specific genes coding proteins 
involved in PI3K and mTOR signaling. Although analyses showed generally instable 
karyotypes and distinct variations of genomic aberrations between all cell models, there 
were no significant gains or losses detected in genes coding for mTOR, P70S6K, S6 
and 4EBP1 (Fig. 44). The same result was obtained when analyzing further key 
molecules involved in mTOR signaling such as TSC1, TSC2, Rheb, and different PI3K 
isoforms (data not shown). Also the gene encoding for AKT1 was predominantly not 
affected by alterations in the investigated cell lines, except in NCI-H2052, which 
obtained a significant loss of this loci (Fig.44). This may represents one aspect 
contributing to the high sensitivity to cisplatin of this cell model, thus AKT signaling is 
thought to be essential for overcoming cell death induction after treatment with platinum 
based chemotherapy [160]. 
Besides genes encoding for key players of the mTOR pathway, we investigated for 
genetic aberrations frequently observed in HMM. Homozygous deletion of 9p21 has 
been reported as one of the most common deletions in malignant mesothelioma [71, 
161]. This locus is located within a cluster of genes including CDKN2A (Cyclin-
dependent kinase inhibitor 2A, p16) and CDKN2B (Cyclin-dependent kinase 4 inhibitor 
B), two tumor suppressor genes which play an important role in cell cycle regulation. Up 
to 72% of investigated HMM cell lines and tumor specimens have been identified to 
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obtain a CDKN2A deletion, which probably makes it to a reliable biomarker of this 
malignancy [162, 163]. Our analyses were absolutely consistent with these findings and 
showed that 5 of 6 cell lines (P31partental, P31res1.2, SPC212, NCI-H28 and NCI-
H2052) had significant deletions of the 9p21 locus. Besides CDKN2A, also the adjacent 
gene encoding CDKN2B was absent in NCI-H28 and NCI-H2052, the latter showing 
further extensive deletions of neighboring loci indicating a complete loss of this 
chromosomal region. Only in SPC111 the 9p21 locus showed no significant aberrations 
compared to all other cell lines. 
Another frequently identified target of genomic alteration associated with HMM 
represents NF2 (Neurofibromin 2, Merlin), which is reported to be mutated in 
approximately half of the cases [162]. This tumor suppressor gene encodes for Merlin, a 
membrane-cytoskeleton scaffolding protein, which is thought to play a critical role in the 
inhibition of cell proliferation and motility through mediating contact-dependent growth 
arrest [164, 165]. In this study we could not detect any significant aberrations of the 
NF2 locus (22q12.2) in none of the evaluated cell lines which indicates that the NF2 
involving pathway rather plays a secondary role in the pathology of present cell models. 
Further aCGH analyses with regard to other important tumor suppressor genes such as 
TP53 and PTEN let us draw the same conclusion. Although both, TP53 and PTEN are 
among the most frequently observed deletions in a multitude of different cancer types, 
this study revealed no alterations of the involving loci in any investigated cell line (Fig. 
45). 
Multiple receptor tyrosine kinases including the epidermal growth factor receptor 
(EGFR), hepatocyte growth factor receptor (HGFR/MET) and insulin-like growth factor 1 
receptor (IGFR), are known to be frequently overexpressed in various types of cancer 
[166]. The highly expression of these oncogenes has also been reported in the case of 
HMM [167-169]. However, aCGH analyses in this study of before mentioned growth 
factor receptors (Fig.45) and associated ligands (data not shown), revealed no 
significant gains of the involving genes. 
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Figure 44.  aCGH analyses of invest igated cel l l ines. Genes encoding the key 
molecules involved in mTOR signaling FRAP1 (mTOR), RPS6KB1 (S6K) and 
EIF4EBP1 (4EBP1) showed no signif icant alterations. Also AKT1, which belongs to 
the main mTOR networking pathways, was only signif icantly lost in NCI-H2052. 
 RESULTS
Investigation into the mode of 
action of temsirolimus 
 
 
93
  
Chr22: NF2 Chr17: P53 Chr10: PTEN
B 
Chr7: EGFR Chr7: MET/HGFR Chr15: IGF1R 
Figure 45. Frequently observed genet ic alterations in caner. (A) The tumor 
suppressor genes encoding NF2, p53 and PTEN showed no signif icant 
alterations. (B) An extract of invest igated oncogenes. EGFR, HGFR(MET) 
and IGF1R showed no signif icant gene amplificat ions of these loci.     
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Figure 46.  Concentrat ion-dependent effects of a 24 h drug temsirol imus exposure 
on DNA-synthesis determined by [3H]-thymidine incorporat ion assay are given 
normalized to untreated controls. DNA synthesis inhibit ion was signif icantly 
stronger in the cisplat in-resistant subline P31res1.2 as compare to the parental 
cell  l ine (p < 0.0001, two way ANOVA).
5.3.2 Effects of temsirolimus on DNA synthesis 
To gain more insight into the growth-inhibitory activity of temsirolimus especially in the 
cisplatin-resistant MPM cell models, impact on DNA synthesis was measured by ³H-
thymidine incorporation. The cell models p31parental, p31res1.2, SPC111 and SPC212 
were exposed for 24h to temsirolimus (range; 1-250ng/ml) and then incubated for 2h 
with radioactive labeled thymidine. DNA synthesis was only marginally affected in 
cisplatin-sensitive cell lines (SPC111, p31parental). In contrast cells more resistant to 
cisplatin (SPC212, p31res1.2) showed a clear tendency of decreased thymidine 
incorporation and a consequently reduced DNA synthesis. 
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5.3.3 Impact of temsirolimus on non-adherent, multicellular HMM spheroid formation 
 In a variety of malignancies serum-independently and non-adherently growing 
multicellular spheroids have been shown to be enriched in a subpopulation of cells 
displaying increased tumor-initiating capacity . In order to investigate whether inhibition 
of mTOR by temsirolimus affects this cancer stem cell-like cell population we have 
generated spheroid cultures from two mesothelioma cell lines SPC111 (Fig. 47 left)  and 
SPC212 (not shown). Importantly, temsirolimus treatment already after four days 
caused progressive loss of HMM spheroid integrity (Fig.47 right upper panel) and 
significantly decreased number as well as mean diameter of spheroids (Fig. 47 right 
lower panel). Considering all these parameters it is apparent that temsirolimus treatment 
has a distinct impact on the tumor-initiating cell compartment of HMM cell lines. 
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Figure 47.  Effects of temsirol imus exposure (100ng/ml) on non-adherent spheroid 
formation of HMM cells were determined after 96 h drug exposure. Representat ive 
photomicrographs of SPC111 cells are shown in the left panel elucidat ing the loss of 
spheroid integrity by mTOR inhibit ion. Impacts on spheroid size and sphere number 
are indicated in the r ight panels. In al l cases, data are means of at least 3 
independent experiments; bars, SD; *, p < 0.05, ***, p ≤ 0.0005, significantly different 
from non-treated cells. 
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5.3.4 Cell cycle alterations induced by temsirolimus 
To elucidate whether temsirolimus induces alterations in cell cycle distribution, we 
performed cell cycle analysis using PI staining and flow cytometry after 48h drug 
treatment. In this analysis we focused again on the differences between rather cisplatin 
sensitive (SPC111, p31parental) and cisplatin resistant cell lines (SPC212, p31res1.2) to 
gain more insight into the striking inverse relationship with respect to temsirolimus 
sensitivity that became obvious in previous experiments. Compared to these significant 
differences as e.g. demonstrated by the impact of temsirolimus on 3H-tymidine 
incorporation primarily in cisplatin-resistant cell models (compare Fig. 46), the effects of 
mTOR inhibition on cell cycle distribution in investigated MPM cell models was rather 
moderate. However, analysis showed a slight increase in G0/G1 phase and decrease in 
S-phase of cell lines representing the rather cisplatin resistant and temsirolimus 
sensitive models (SPC212, P31res1.2; Fig.48). In contrast cell lines with less sensitivity 
to temsirolimus showed almost no changes of populations in G0/G1 phase but a 
distinct increase of the S-phase fraction. Nevertheless, with regard to cell models 
obtaining increased G0/G1 phase, these results demonstrate the expected effects on 
temsirolimus-sensitive cell models, as mTOR-inhibition is known to prevent transition 
into S-phase [170]. 
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Figure 48. Inf luence of temsirol imus treatment as single agent at the indicated 
concentrat ions, on cycle progression in HMM cells was determined by FACS 
analyses after 48h continuous drug exposure. Cel l  models are compared to 
appropriate temsirolimus sensit ivit ies [SPC111(Tem-resistant) vs SPC212  (Tem-
sensit ive), upper panel; P31parental (Tem-resistant) vs P31res1.2 (Tem-
sensit ive)] (a.u=arbitrary unit). 
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5.4 Combination tests with temsirolimus and cisplatin 
5.4.1 Impact on cell viability 
The following assays were performed to investigate whether targeted inhibition of mTOR 
by temsirolimus in combination with cisplatin might exert synergistic antiproliferative 
effects. To implement a possible relation between growth inhibition and time of drug 
exposure we analyzed changes in cell viability by 72 h MTT survival assays (short-term) 
(Fig.49) and ~7d clonogenic assays (long-term) (Fig.51). The MTT assays showed that 
the combined treatment of temsirolimus and cisplatin overall significantly decreased the 
number of viable cells even at low concentrations demonstrating a stronger effect in all 
HMM cell lines than that of cisplatin or temsirolimus alone. In all investigated cell 
models, predominantly synergistic anticancer effects were observed independent of the 
responsiveness of the HMM cell lines to both single agents (compare Fig. 41 and 43). 
This was validated by the calculation of combination indices (CI) (compare Material and 
Methods) whereby values < 0.9 indicate synergism, >1.1 antagonism, and all other 
values additive activity (Fig. 50). However, the strongest synergistic activity of both 
agents was observed in cell lines with rather cisplatin resistance (SPC212, NCI-H28, 
and P31res1.2). 
Clonogenic survival assays were performed with SPC111, SPC212, P31parental and 
P31res1.2 and confirmed both the synergistic anticancer activity of the combined 
treatment and the enhancement of temsirolimus sensitivity by induction of cisplatin 
resistance (Fig. 51). Besides the observed inverse responsiveness of investigated cell 
lines to both agents the combination of temsirolimus and cisplatin within this long-term 
analysis inhibited the proliferation of cell clones up to 99% compared to the untreated 
control. 
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Figure 49. Activity of temsirol imus (Tem) combined with cisplat in (Cis) 
against human HMM cell l ines after 72h exposure. Changes in cel l viabil ity 
were measured by MTT assay. 
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Figure 50. Data from Fig.49 are given as combination indices (CI) calculated 
fol lowing the method of Chou and Talalay by using CalcuSyn Software. 
Values < 0.9 represent synergism, 0.9-1.1 addit ive act ivit ies, and > 1.1 
antagonism. 
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olimus was used at 100ng/ml. After seven days cont inuous drug exposure 
cells were stained with crystal violet, representative photomicrographs were 
taken (left) and colonies were counted. Data from three experiments are 
given normalized to controls (right). Stat ist ic bars, SD; **, p < 0.05, ***, p ≤ 
0.0005, significant ly different from non-treated cells. Signif icance levels 
immediately upon the SD bars represent comparisons with the untreated 
control.  
Figure 51.  Effects of long-
term exposure to temsirol imus 
as single agent and in 
combinat ion with cisplatin on 
colony formation of SPC111, 
SPC212, P31 and P31res1.2 
were established. Cell l ines 
sensit ive to cisplat in (SPC111 
;P31res1.2) were treated with 
1μM those comparably res-
istant (SPC212; P31res1.2), 
with 2.5 μM cisplat in. Temsir-   
 
         
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Ci
s
Te
m
Ci
s+
Te
m Ci
s
Te
m
Ci
s+
Te
m Ci
s
Te
m
Ci
s+
Te
m Ci
s
Te
m
Ci
s+
Te
m
0.0
0.2
0.4
0.6
0.8
1.0
1.2
fo
ld
 c
on
tr
ol
**
**
**
 ** 
**
**
**
*
**
*
**
**
**
*
**
**
**
*
SPC111 SPC212 P31parental P31res1.2 
* 
 RESULTS
Combination tests with 
temsirolimus and cisplatin 
 
 
102
5.4.2 Impact on apoptosis induction 
In order to investigate the role of apoptosis induction on the synergism of temsirolimus 
and cisplatin, Hoechst-propidium iodide staining of exposed MPM cells was performed 
and the proportion of cells with condensed chromatin counted (the P31 resistance 
model is representatively shown in Fig. 52). As expected, cisplatin at 5μM induced 
strong G2/M cell cycle arrest (large nuclei in the Hoechst staining) in both cell models 
but apoptosis predominantly in the parental cell line (quantification in Fig.53). 
Temsirolimus (250ng/ml) induced only in the cisplatin-resistant subline a significant 
increase of apoptotic cells, thus again confirming the inverse relationship of 
chemotherapy and mTOR inhibition response. Apoptosis induction was dramatically 
enhanced especially in P31res1.2 by combination of both agents inducing up to 75% 
apoptotic nuclei. This was also reflected by analysis of cleavage of the caspase 
substrate Poly (ADP-ribose) polymerase (PARP) which represents a notable marker for 
apoptosis. This enzyme is involved in a number of cellular processes such as DNA-
repair and becomes cleaved by proteolytic degradation in cells sustaining extensive 
DNA damage and initiating programmed cell death.      
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Figure 52. Representat ive photomicrographs show impact of temsirol imus and cisplat in as 
single agents or in combinat ion on apoptosis induct ion after 48h drug treatment. ( large 
pictures show Hoechst-stained nuclei of al l  cel ls (viable/apoptotic/dead); small pictures 
show PI-stained nuclei of dead cel ls. For quant itative analyzes see Fig.53.  
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5.4.3 Impact on cell cycle distribution 
To identify alterations in cell cycle distribution induced by the combination of mTOR 
inhibition and chemotherapy, MPM cell lines were treated with temsirolimus and 
cisplatin at different concentrations for 48h before performing cell cycle analyses by PI 
staining and flow cytometry (Fig. 54). Cisplatin as single agent induced a severe and 
almost complete G2/M arrest in SPC111, SPC212 and P31parental already at 2.5 μM, 
while P31res1.2 which represents the cell line with highest cisplatin resistance showed 
approximate results only at the maximum concentration (5μM). Interestingly, in 
responsive cell models (SPC111, P31), G2/M arrest was less pronounced at 5 μM and 
***
***
***
***
PAR
cl.PAR
Figure 53. Quantitat ive analyzes of apoptot ic rates were determined by 
f luorescence microscopic evaluat ion of Hoechst 33342-stained P31 and 
P31res1.2 cells after 48h drug exposure (upper panel). Data show the mean 
percentage of apoptot ic cel ls of at least 3 independent experiments (bars, 
SD; *, p < 0.05, ***, p ≤ 0.0005). Lower panel demonstrates cleavage (cl. 
PARP) of the caspase-substrate PARP as an indicator of apoptotic cel l death 
detected by immunoblot. 
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Figure 54.  Inf luence of temsirol imus and cisplat in treatment, both as 
single agent and in combinat ion at the indicated concentrations, on cycle 
progression in HMM cells was determined by FACS analyses after 48h 
cont inuous drug exposure. 
paralleled by an increase of cells arrested in S-phase or G0/G1-phase in SPC212 
respectively. As described before (s.ch. 4.3.3), temsirolimus as single agent showed 
rather moderate effects on cell cycle alterations but in combination with chemotherapy 
distinctly inhibited G2/M cell cycle arrest by cisplatin leading to an enhanced 
accumulation of cells in S-phase and/or G0/G1-phase. Only in the cisplatin-resistance 
subline P31res1.2 this effect was less distinct. 
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5.4.4 Impact on molecular changes 
In order to elucidate the molecular basis of the observed synergisms between mTOR 
inhibition and chemotherapy, the impact of temsirolimus and cisplatin alone and in 
combination on the activation of mTOR and downstream signal mediators was 
investigated in HMM cell lines by immunoblot (Fig. 55). Temsirolimus induced a distinct 
downregulation of p-mTOR but also total mTOR which was especially pronounced in 
temsirolimus-sensitive cell lines (SPC212, P31res1.2). Accordingly, phosphorylation of 
the downstream signal mediators was reduced significantly (p-P70S6K, p-4EBP1) or 
almost completely (p-S6). Cisplatin enhanced blockade of mTOR activation and 
downstream signals by temsirolimus especially at the level of 4EBP1. This synergistic 
effect was notably apparent in the temsirolimus-resistant cell lines (SPC111, 
P31parental). 
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Figure 55.  Expression and phosphorylat ion state were analyzed for mTOR 
and its downstream mediators as indicated by Western blott ing. β-actin 
antibody served as loading control. 
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5.5 In vivo experiments 
5.5.1 Effect of temsirolimus as single agent on HMM xenografts in SCID mice 
To examine whether the in vitro activity of temsirolimus against MPM cells translates 
into in vivo anticancer effects, HMM cells were xenografted intraperitoneally in SCID 
mice. SPC111 and P31parental were tumorigenic leading to intraperitoneal tumor seed 
and hence used for subsequent experiments. Two weeks after tumor cell inoculation 
mice were randomized into two treatment groups receiving either solvent or 
temsirolimus as described in the Material and Methods. Drug treatment was well 
tolerated by all mice with no notable toxicity through the entire experiment. In the first 
experiment accomplished with SPC111, tumor weight was measured in all animals 38 
days after transplantation when the first control animal had to be sacrificed. 
Temsirolimus led to a noticeable decrease of the intraperitoneal tumor burden (Fig. 56A) 
demonstrated by a significant weight reduction of harvested tumor nodes compared to 
the untreated control (Fig. 56B). 
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Figure 56. (A) Impact of temsirol imus in vivo as single agent demonstrated by 
representat ive photographs of SCID mice peritoneum (arrows show tumor 
nodules).(B) Intraperitoneal tumor growth was determined 38 d fol lowing 
engraftment. Peritoneal tumor growth in a representat ive control (Cnt) and 
treated (Tem) animal (A) is opposed to quant if ication of the tumor weight in all 
animals given by box-plot (median tumor weight: 225 mg (control) vs. 48 mg 
(temsirolimus). 
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In order to verify whether this remarkable anticancer effect prolongs survival, 
consecutive experiments using both xenograft models SPC111 and P31parental were 
performed and terminated not until enhanced tumor progression (for details see Material 
and Methods). The results demonstrated a significant prolonged survival of both models 
treated with temsirolimus (Fig. 57, left panel) paralleled by a dramatically tumor weight 
reduction (Fig 57, right panel). 
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Figure 57. Impact of temsirol imus treatment on overal l survival of SCID mice 
is shown as Kaplan Meier curves (mean overal l survival for SPC111: 52days 
[control] vs. 62 days [temsirol imus]; log rank test: p = 0.018; mean overal l 
survival for P31: 45 days [control] vs. 57 days [temsirol imus]; log rank test: 
p = 0.002). Box-plots (r ight panel) show tumor weight at death. 
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5.5.2 Molecular effects of temsirolimus as single agent on tumors in HMM xenografted 
SCID mice 
To prove target interference, protein extract of control and temsirolimus-treated tumors 
were prepared 48h after the last treatment and analyzed for activation of mTOR and 
respective downstream signal mediators. As shown in Fig. 58, phosphorylation of 
mTOR and its downstream targets was severely reduced or completely inhibited by 
application of temsirolimus in vivo. 
      
 
 
 
 
 
 
 
 
 
 
 
In order to perform histological analyses, SPC111 xenograft tumors were harvested 
from cumulative survival experiment (s. 4.5.1) and processed by routine methods (s. 
Materials and Methods). Even at this setting when treated mice had to be sacrificed due 
to tumor progression (several weeks after the last temsirolimus treatment), 
phosphorylation of mTOR was distinctly attenuated as compared to the control tumor 
and restricted to the proliferating outer cell layer (Fig.59, lower panels). As obvious from 
both H&E and Ki67 proliferation marker staining (Fig. 59, upper three panels), 
temsirolimus treatment resulted in dramatic induction of necrotic areas in the center of 
tumor nodules frequently leaving only a narrow rim of vital tissue. Especially at the 
border of vital to necrotic areas massive cell death was confirmed by TUNEL staining 
which was widely absent even in the center of larger tumor nodules of solvent-treated 
control mice (Fig. 60). 
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Figure 58.  impact of temsirolimus treatment on 
act ivat ion of mTOR and several downstream effectors 
in the HMM xenograft t issue (two days after the last 
treatment) was analyzed by Western blot. 
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Figure 59.   Histological evaluat ion 
was performed for SPC111 HMM 
tumors grown in SCID mice and 
representat ive temsirol imus (Tem)- 
or solvent-treated control (Cnt) 
cases are shown. H&E stainings at 
two different magnif ications are 
opposed to iummunostainings for 
Ki67 (prol iferation marker) and 
phosphorylat ion of mTOR using 
consecut ive sect ions. 
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Figure 60.  TUNEL staining (cel ls with red nuclei) was performed on 
sect ions as under Fig. 59 to indicate programmed cell death in HMM 
xenograft t issues. (Blue, nuclear counter stain by DAPI). 
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5.5.3 Effect of temsirolimus in combination with cisplatin on HMM xenografts in SCID 
mice 
Finally, we investigated the activity of temsirolimus in combination with cisplatin against 
the SPC111 MPM xenograft model (Fig. 61). Both overall survival of mice (Fig.61, left 
panel) and the reduction of tumor weight (Fig.61, right panel) were significant for both 
single agent therapies but further enhanced in the combination setting.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 61. Anticancer activity of temsirol imus and cisplat in as single agents or in 
combinat ion was determined against the SPC111 xenograft in SCID mice and 
survival curves ( left  panel) (mean overall  survival: 46 days [control] vs. 60 days 
[temsirol imus] vs. 71 days [cisplat in] vs. 83 days [temsirol imus/cisplatin]; log rank: 
p = 0.000) are opposed to tumor weight (right panel) (median tumor weight: 402 
mg [control] vs. 259 mg [cisplat in] vs. 178 mg [temsirol imus] vs. 123 mg 
[temsirol imus/cisplatin]) at t ime when animals had to be sacrif iced due to tumor 
progression. 
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6. DISCUSSION 
Human malignant mesothelioma (HMM) is a highly aggressive type of cancer that 
affects the lining of certain serosal body cavities, particularly the pleura and peritoneum 
but in fewer cases also the pericardium and tunica vaginalis. HMM is strongly 
associated with asbestos exposure and shows a 20 – 50 year latency period. Because 
of the extensive asbestos usage in the last century primarily in western industrial 
countries, an increasing incidence is prognosticated for the next decades. As current 
standard HMM chemotherapy regimen the combination of the platinum-based 
compound cisplatin and the multi-targeted anti-folate pemetrexed is used attaining a 
median survival for treated patients of nine to twelve months [171]. This prospect 
demonstrates that current therapy options only show modest benefits. Consequently, 
the development of novel approaches to fight this devastating malignancy is urgently 
needed. 
In this study we demonstrate that 1) a distinct phosphorylation of the major oncogenic 
signal transducing factor mTOR is present in the majority of HMM tumor specimens and 
in investigated cell models 2) gene dose alterations of tumor suppressor genes and 
proto-oncogenes, as p53 and PTEN as well as several types of growth factor receptors, 
respectively, may only play a secondary role in the pathogenesis of at least in this study 
investigated HMM cell lines 3) inhibition of mTOR by the small-molecule compound 
temsirolimus as a single agent distinctly attenuated HMM cell growth in vitro and tumor 
formation in vivo; 4) mTOR inhibition was particularly effective against HMM cells with 
intrinsic or acquired resistance against both cisplatin and pemetrexed, components of 
the current standard HMM chemotherapy regimen [172] and 5) temsirolimus synergized 
with cisplatin against HMM models in vitro and in vivo. 
6.1 The role of mTOR in HMM 
Immunohistochemical analyses of HMM clinical specimen (N=70) showed a significant 
hyper-phosphorylation of mTOR in the tumor compartment but not in the surrounding 
stromal tissues, thus indicating an interrelation between aberrant mTOR signalling and 
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HMM development. This conclusion is emphasized by similar findings reported in two 
other independent series (N=26; N=41) of mesothelioma samples [173, 174].   
However, our analysis revealed that mTOR hyper-activation cannot be associated with 
every histological subtype of HMM and demonstrated distinct differences.  In our HMM 
panel, p-mTOR expression was clearly more pronounced in lesions with epitheloid as 
compared to sarcomatoid histology. In biphasic tumors again the immunoreactivity for 
activated mTOR was mainly restricted to the areas with epitheloid differentiation. To our 
knowledge, an association of mTOR activation and histological subtype of 
mesothelioma has not been reported before. 
Nevertheless, it is still not clear which underlying causes are actual responsible for the 
development of sarcomatoid or mixed phenotype of tumor cells in a mesothelial tissue 
as the pleura. Due to sarcomatoid cancer cells share cytological and/or molecular 
properties of both epithelial and mesenchymal tumors, epithelial-to-mesenchymal 
transition (EMT) seems to be a process obviously involved in this histological 
transformation. Indeed, in some extent this may also explain the even poorer prognosis 
of patients suffering from sarcomatoid tumors, as EMT is characterized by loss of cell 
adhesion, repression of E-cadherin expression and increased cell motility [175, 176]. All 
these factors are known to confer aggressive tumors high invasiveness and 
chemoresistance. Actually it has been reported that EMT seems to play an important 
role in the development of asbestos induced lung diseases as fibrosis and 
mesothelioma [177]. Further biphasic HMM tumors may be considered as a true 
intermediate, as they are thought to contain cell types which have undergone EMT 
and/or the reverse mesenchymal-to-epithelial transition (MET) in the identical tissue 
[178]. Interestingly, it has been shown in diverse systems that the Pi3/AKT/mTOR 
pathway is a decisive factor in the EMT process. Our data regarding almost general 
restriction of mTOR phosphorylation to cases/regions with epithelial differentiation 
suggest that this pathway either might inhibit EMT or promote MET of transformed 
mesothelial cells. Accordingly, promotion of both epithelial differentiation and 
proliferation by mTOR signalling was demonstrated in mammary epithelial cells [179]. In 
contrast several other studies have indicated an essential role of the AKT/mTOR signal 
pathway in the execution of EMT in diverse cell types including murine mammary 
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epithelial cells [180] and even peritoneal mesothelial cells [181]. Consequently, the 
specific role of mTOR in (de)differentiation process during HMM progression needs to 
be determined in further studies.  
Besides epitheloid differentiation, mTOR activation was particularly high in early-stage 
disease but negative in non-malignant tissues. This indicates that activation of mTOR 
might be a relatively early oncogenic event during the progression of HMM as also 
observed in early stage lung adenocarcinoma [182]. This assumption is also supported 
by other studies demonstrating that the mTOR upstream signal mediator AKT is 
activated in mouse mesotheliomas induced by intraperitoneal crocidolite asbestos 
injection [173] and early in asbestos-induced malignant transformation of human 
mesothelium [76]. Altogether, both factors, epitheliod subtype and early-stage disease, 
which seem to be strongly associated with mTOR hyper-activation, provide good 
prerequisites for a toehold in mTOR targeting. The majority of HMM patients are 
diagnosed with this histological type and a multitude of different studies have reported 
that generally targeted compounds, as the mTOR inhibitor temsirolimus, show best 
results applied in early tumor progression [183, 184]. 
With regard to our further in vitro analyses, all investigated HMM cell models showed a 
constitutively active mTOR pathway, as previously also found in other mesothelioma cell 
models [185]. This leads to the assumption that mTOR has not only a high relevance in 
early HMM development but also plays an important role in the continuous progression 
of this tumor. So what could this role be? The mTOR pathway is generally known to be 
centrally involved in the control of tumor cell metabolism, growth and proliferation in 
many different types of cancer [186]. Nevertheless, differing results from studies 
investigating mTOR as molecular target in cancer therapy and data from clinical trials 
with current inhibitors reflect the complexity of the mTOR signalling network. The two 
functionally distinct mTOR complexes, parallel regulatory pathways, and several 
feedback loops contribute to variable functions of this pathway and make it difficult to 
clearly determine its significance for each type of cancer. However, it is assumed that 
the PI3K/AKT/mTOR axis confers a significant survival benefit for HMM cells, helping to 
survive cytotoxic damage caused by asbestos fibers, which are considered to be the 
main cause of mesothelioma [187]. In that study both PI3K/AKT and mTOR signaling 
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have been demonstrated to be, in an apparently independent manner, important for the 
survival of mesothelial cells treated with asbestos. Elevated levels of calretinin, also 
known as a useful biomarker for mesothelioma, seem to obtain cytoprotective effects 
mediated via hyper-activation of the PI3K/AKT pathway. However, also mTOR has been 
shown to mediate a survival benefit but independent of the present calretinin level. 
Concerning the competence of tumor cells to metastasize, mesothelioma cells could be 
demonstrated to be highly dependent on mTOR in terms of spreading capability [185]. It 
is suggested that adhesion and spreading of mesothelioma cells on the extracellular 
matrix (ECM) require the continuous translation of pre-synthesized mRNAs, controlled 
by the mTOR pathway. Also a direct cytoskeletal remodeling by mTORC1 may be 
responsible for increased cell motility.  
6.2 Genomic and molecular aberrations in HMM 
In this study we investigated genomic alterations of HMM cell lines via array 
comparative genomic hybridization (aCGH) and focused on both, genes encoding for 
key players and regulators of the mTOR pathway and frequently mutated loci generally 
associated with cancer pathology. Analyses with regard to the mTOR pathway showed 
neither significant gains nor losses of the involved genes. This is not surprising 
considering the fact, that oncogenic mTOR signaling in HMM has not yet been reported 
in association with altered gene dose of the directly involved mediators such as S6K, S6 
and 4EBP1. More likely considered are dysfunctioning regulatory mechanisms such as 
the PI3K/AKT pathway and key factors involved in energy metabolism, to be 
responsible for mTOR hyper-activation. However, also these networking molecules 
showed no significant gene copy alterations in the investigated cell lines in our study, 
indicating that genomic aberrations are rather no major players behind deregulated 
mTOR control mechanisms. Indeed, this is in accordance with several other studies, 
which have reported that at least genomic mutations of the mTOR upstream key 
mediators AKT and PI3K are rather an uncommon event in HMM pathology [188]  (). 
Data on genomic alterations in the negatively regulator of these molecules, PTEN, which 
is known as one of the most commonly lost tumor suppressors in human cancer, are 
conflicting [189, 190]. None of our analyzed cell lines showed a deletion of the PTEN 
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locus.  Nevertheless, several observations have suggested that the Pi3K/AKT/mTOR 
pathway might be hyper-activated in mesothelioma cells at least in vitro either at the 
level of mTOR or the upstream signal mediator AKT [76, 150, 173, 191, 192]. 
Accordingly, p-mTOR expression correlated significantly with activation of AKT in 
human and murine mesothelioma cell lines [173]. In that study both hepatocyte growth 
factor/cMet signalling and inactivation of the negative AKT regulator PTEN were 
suggested as mediators of AKT hyper-phosphorylation. Further it has been reported, 
that expression of PTEN was a strong predictor of mesothelioma patient survival [190] 
and adenoviral overexpression of PTEN in HMM cells induced massive apoptosis [193]. 
At this point, it is worth noting, that independently of the genomic pattern, altered PTEN 
expression may be a consequence of other associated dysfunctioning regulatory 
networks. Actually, suppressed PTEN expression by a deregulated balance between 
Notch-1 and -2 and consequently upregulation of AKT phosphorylation were suggested 
to contribute to the malignant phenotype of mesothelioma cells especially under 
hypoxic conditions [194]. Moreover, there is evidence, that AKT hyper-activity is not 
necessarily inhibited in the presence of PTEN. In a series of diffuse malignant peritoneal 
mesothelioma tumor specimens (n=20), 95% showed significant phosphorylation of 
AKT, mTOR and its downstream mediators, although PTEN showed a normal disomic 
pattern and was expressed in almost all samples [195]. In addition to oncogenic signal 
pathways, also a direct activation of AKT by SV-40 was suggested to be involved in 
asbestos-induced mesothelial cell transformation [76].  
Regardless of the interplay between AKT and mTOR phosphorylation, we investigated 
for other potential genomic aberrations which may contribute to the constitutive 
activation of mTOR in HMM. Given that mTOR is highly regulated by the activity of 
multiple receptor tyrosine kinases (RTKs) such as EGFR, HGFR (MET), IGF1R and their 
associated ligands (data not shown) we analysed the genomic pattern of these major 
growth factors. Also in this case, no significant gains of the involved genes were 
detected in any cell line. The role of EGFR generally in the development of HMM seems 
to be highly controversial. Some studies reported that there was no relationship 
between EGFR over-expression and outcome in patients with mesothelioma [196-198], 
while others have reported that EGFR over-expression is associated even with 
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improved prognosis [199, 200]. Anyway, two phase II clinical trials based on EGFR 
tyrosine kinase inhibitor (gefitinib) therapy have not shown promise in mesothelioma 
therapy so far [201, 202], although the majority of patients exhibited EGFR 
overexpression. It is hypothesized that resistance to gefitinib may be caused by to the 
over-expression of alternative RTKs which compensates for the loss of EGFR function 
[167]. Interestingly, downstream proteins within the EGFR signaling pathway, such as 
AKT and mTOR, have been shown to be utilized by HGFR and IGF1R in case of EGFR 
inhibition. Even though our study could not reveal at least genomic alterations of HGFR 
and IGF1R, several research groups have suggested that both growth factor receptors 
take a key position in HMM pathology [203, 204]. With regard to the possibility that 
downstream mTOR activation plays an essential role in the oncogenic signaling of all 
three RTKs and that the inhibition of one only leads to the activation of compensatory 
“by-pass” mechanisms, we suggest that mTOR inhibition could strikingly diminish this 
escape axis. 
In order to investigate frequently observed genomic alterations highly associated with 
HMM, we focused on NF2 (Neurofibromin 2 or Merlin) and CDKN2A (Cyclin-dependent 
kinase inhibitor 2A/ p14ARF and p16INK4A). Mutations of the tumor suppressor gene Merlin 
(22q12.2) occur in approximately half of HMM cases [162] and are thought to be 
potentially linked with asbestos exposure [205]. Although chromosome 22 is known to 
be recurrently lost in HMM [206] we could not detect any genetic loss in this case and 
no significant aberrations of the NF2 loci in the analyzed cell models. Interestingly it has 
been reported that Merlin regulates mTORC1 activity in a PI3K/AKT and MAPK/TSC2 
independent manner in human meningioma [207] and also HMM [208]. Furthermore, 
both studies demonstrated that Merlin-deficient cell lines exhibited constitutive 
mTORC1 activation and showed increased sensitivity to mTOR inhibition. Although in 
our study we could not reveal a relation between NF2 loss and the observed 
constitutive activation of mTOR, the mentioned studies again reflect that mTOR 
targeting may provide promising effects in the treatment of HMM. 
The tumor suppressor gene CDKN2A, which is deleted in the vast majority of HMM 
cases [162, 209, 210], provides the two alternative reading frame (ARF) products p14ARF 
and p16INK4A. Both are cyclin-dependent kinase (CDK) inhibitors and involved in cell 
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cycle regulation. The frequently observed mutations absolutely correlated with our 
study, which showed significant losses of CDKN2A in 5 of 6 cell models, one with an 
obviously heterozygous deletion. As p14ARF normally inhibits the p53 negative regulator 
MDM2 and therefore regulates the protein stability of p53, loss of p14ARF consequently 
prevents p53 expression. This is significant considering that TP53 mutations have been 
detected in a multitude of tumors, but they are not a very prominent feature in HMM 
[162]. Indeed, also the cell models investigated in this study showed no aberrations of 
the TP53 locus. Apparently, loss of p53 constitutes no essential event in the 
development of HMM, as in most cases p53 expression is inhibited anyway based on 
the loss of p14ARF. If carcinogenesis is considered to underlie “Darwinian mechanisms” 
[7], this instance would reflect the absence of selective pressure.  
6.3 Targeting mTOR – in vitro 
Regardless of the upstream mechanism of the pathway activation, our data suggest 
that mTOR is an ideal point for therapeutic intervention. First, mTOR inhibitors like 
temsirolimus are already approved for therapy of other solid tumors like renal cell cancer 
[149]. Additionally, we demonstrate in this study that temsirolimus does not only target 
HMM cells in adherent monolayer cultures but also as non-adherent spheroids believed 
to be enriched in “cancer stem cells” with enhanced tumor-initiating capacity [9]. This 
cell compartment is frequently responsible for systemic therapy resistance of solid 
tumors [211]. Temsirolimus led to growth inhibition and disintegration of HMM 
spheroids. In a series of publications it was demonstrated that growth of human 
mesothelioma cells as tumor fragment-derived spheroids [212] or multicellular non-
adherent spheres leads to resistance against drug-induced apoptosis [150]. This 
therapy insensitivity was based at least in part on hyper-activation of mTOR interfering 
with mitochondrial apoptotic pathways activation [76]. Together with our observations 
these data suggest that mTOR inhibition should not only lead to HMM growth inhibition 
even in the “cancer stem cell compartment” but also to reversal of intrinsic and/or 
acquired resistance to chemotherapy. 
Indeed, we detected a distinct synergism between mTOR inhibition and the routine 
HMM chemotherapeutic agent cisplatin in vitro an in vivo. With regard to the in vitro 
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situation, comparable observations have been published recently by Hartman et al. 
demonstrating that sirolimus enhances cisplatin-induced cell death in HMM cells [192]). 
Also in several other cancer types such as ovarian, endometrial, neuroectodermal and 
lung cancers [213-216], mTOR inhibitors showed efficient chemosensitizing properties 
by increasing cisplatin-induced apoptosis. Accordingly, hyper-activation of the 
PI3K/AKT/mTOR signal pathway were indicated to be responsible for cisplatin 
resistance induced by e.g. the adenoviral E1a gene [217] and insulin-like growth factor 
receptor I (IGFR-I) [218]. In our study, both enhanced apoptosis induction and altered 
interference with cell cycle progression was underlying the synergism between cisplatin 
and temsirolimus. With regard to the inhibition of downstream signals, a synergistic 
blockade of 4EBP1 phosphorylation by the combination approach was especially 
prevalent. Accordingly, regulation of eIF4E by 4EBP1 phosphorylation and related cap-
dependent translation was demonstrated to be a key factor in mTOR-mediated pro-
oncogenic and anti-apoptotic signals [219]. 
In addition to the synergism between chemotherapy and mTOR inhibition, we found 
that intrinsic as well as acquired cisplatin resistance is generally accompanied by hyper-
sensitivity against mTOR inhibition. In a cell model containing a sensitive parental and a 
cisplatin-resistant cell (sub)line, we demonstrate that temsirolimus hyper-susceptibility is 
based on potent apoptosis induction in the resistant cell model. Comparable sensitation 
against mTOR inhibition as a consequence of cisplatin resistance was also observed in 
ovarian (19) and lung cancer [220] in this cases based on upregulation of mTOR 
phosphorylation or AKT gene amplification, respectively. Interestingly, we did not 
observe a forced upregulation neither of the mTOR or AKT pathway (data of the latter 
not shown) activity in the cisplatin-resistant cell models suggesting that enhancement of 
these pathways is not directly responsible for the chemotherapy resistance. Our data 
rather suggest that cisplatin-resistant cell lines develop forced “addiction” to continuous 
mTOR signals. Accordingly, temsirolimus as single agent resulted in an almost complete 
dephosphorylation of S6 in all cell lines whereas the decrease of the p-4EBP1 level was 
significantly stronger in cisplatin-resistant phenotypes. As mentioned previously, it is 
thought that hyper-activation of the IGFR-I signalling pathway is an important event for 
cisplatin resistance [218] and also associated with an increase in both mesothelioma 
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cell proliferation and motility [204]. Interestingly it has been demonstrated, that 
stimulation with IGF-I in HMM cell lines directly correlates with increased 
phosphorylation of 4E-BP1 which was highly dependent on AKT/mTOR signalling [221]. 
Blockade of cap-dependent translation by transfection with constitutively active 4EBP1 
inhibited IGF-I mediated proliferation and motility. If indeed the cisplatin resistant 
phenotype is mediated at least in part of IGFR-I hyper-activation, these data would 
contribute to our assumption of a forced “addiction” to continuous mTOR signals. The 
molecular mechanisms underlying this vulnerability of mTOR downstream survival 
signals in cisplatin-resistant cell models need to be investigated in further experimental 
approaches. 
With regard to the impact of pemetrexed on HMM cell lines, we observed that cytotoxic 
effects were significantly reduced in those with cisplatin resistance. This got obvious 
especially comparing P31parental and its cisplatin-resistant subline. These results 
should give cause for concern, considering that the combination of cisplatin and 
pemetrexed presents the HMM first-line therapy. However, the underlying molecular 
background responsible for this multi-drug resistance is still unclear, but our ongoing 
studies have focused on this issue.    
6.4 Targeting mTOR – in vivo  
To the best of our knowledge this is the first report that mTOR inhibition distinctly 
attenuates human HMM growth in vivo as xenografts in SCID mice. Both, significantly 
reduced tumor mass and prolonged overall survival were observed accompanied by 
massive tumor necrosis. The inhibition of the molecular target of temsirolimus in vivo, 
namely downregulation of tumor-associated mTOR phosphorylation, was demonstrated 
immediately after therapy but still persisted for several weeks following the last 
temsirolimus administration. The profound reduction of tumor load might be based on 
massive tumor cell death demonstrated by TUNEL staining mainly at the junction to the 
necrotic areas. Moreover, temsirolimus is known to exert potent antiangiogenic activities 
[222, 223], which might support the development of central tumor necrosis. As 
discussed, spreading of mesothelioma cells is believed to be highly dependent on 
mTOR signalling, indicating that the significantly prolonged survival of temsirolimus 
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treated mice was at least in part caused by an effective inhibition of tumor metastases. 
Both aspects, abolished angiogenesis and suppressed cell motility, are obviously 
important factors contributing to a forced response to mTOR inhibition in vivo of cells 
which were rather temsirolimus insensitive in in vitro experiments. 
In addition to the distinct activity of temsirolimus as a single agent against HMM 
xenografts, we also have performed an initial experiment for combination with cisplatin. 
As expected from the in vitro analyses, the combination approach exhibited synergistic 
anti-cancer effects against HMM xenografts. These experiments were done so far only 
in one combination setting using concurrent applications of cisplatin and temsirolimus. 
Currently, experiments are underway testing different settings involving on the one hand 
also pemetrexed and on the other hand applying temsirolimus after therapy failure with 
cisplatin.  
In summary we present in this study strong evidence that temsirolimus is active against 
human HMM in vitro and in vivo, shows hyperactivity against cisplatin-resistant cells, 
and synergises with platinum-based chemotherapy. This suggests further investigation 
of mTOR inhibition as a promising treatment strategy for human HMM either in 
combination with chemotherapy to avoid resistance development or as second-line 
treatment following chemotherapy failure.  
CONCLUSION 
 
 
123
7. CONCLUSION 
Due to the very poor clinical response and rising incidence of HMM, the past years have 
seen a considerable increase in the clinical and epidemiologic significance of this 
devastating malignancy. Although the usage of asbestos has been continuously 
restricted since the late 1980s, it is predicted that the peak in incidence is reached not 
before the next two or three decades. Main reasons are the long latency period after 
asbestos exposure and the proceeding usage of asbestos in developing countries. 
Hence, further research is urgently needed to advance therapeutic strategies and the 
understanding of HMM pathology. 
In this study, the cytogenetic analyses underline the complexity and heterogeneity of 
chromosomal aberrations in HMM, most notably with regard to the PTEN locus. In 
contrast to findings of other research groups, we could not detect a deletion of PTEN in 
any investigated cell models. On the other hand, the frequently reported association of 
HMM with loss of CDK2A, has been confirmed in this study, indicating a reasonable 
explanation for the lacking incidences of p53 deletions in HMM. For this reason, we 
suggest that a possible implementation of CDKN2A as predictive biomarker for HMM 
should be considered. 
Furthermore, we show that mTOR is constitutively activated in HMM tumor specimen 
and cell lines, highlighting the important role of this oncogenic mediator in HMM 
pathology. Also there is strong evidence that inhibition of mTOR with the targeted 
compound temsirolimus leads to striking  anticancer effects against HMM in vitro and in 
vivo, shows hyperactivity against cisplatin-resistant HMM cells, and synergises with 
platinum-based chemotherapy. This suggests that acquired and intrinsic resistance of 
HMM against cisplatin is very complex and not primarily based on transporter-mediated 
mechanisms. With regard to the observed reduced cytotoxic effects of pemetrexed in 
cisplatin resistant cell models, we also assume that the combination of these agents, 
which constitutes the present standard therapy regimen, may be counterproductive, at 
least in particular cases. 
Taken together we assume that mTOR inhibition may be a promising treatment strategy 
for human malignant mesothelioma either in combination with chemotherapy to avoid 
resistance development or as second-line treatment following chemotherapy failure. 
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8. ABBREVATIONS  
 
ABC ……….………… ATP-binding cassette  
ATP …………..……… Adenosine triphosphate  
BSA ………..….…… Bovin serum albumin  
CDK ……………..…... Cyclin-dependent kinase  
Cisplatin ….………..... cis-diamminedichloroplatinum(II)  
DAPI …………..…….. 4',6-diamidino-2-phenylindole  
dATP ……………....... Deoxyadenosine triphosphate  
DMSO …….....………. Dimethyl sulfoxide  
DNA ………...……….. Deoxyribonucleic acid  
EGFR …………..…..... Epidermal growth factor receptor  
FACS ……..…………. Fluorescence-activated cell sortiment ABBREVATIONS  
FCS …………………..  Fetal calf serum  
HGF ……………….…. Hepatocyte growth factor  
HIF-1........................... Hypoxia inducible factor-1 
HMM ………………… Human malignant mesothelioma  
IGF ………………….... Insulin-like growth factor  
MAPK ……………....... Mitogen activated protein kinase 
MPM ………………… Malignant pleural mesothelioma  
MTT ………..………… Dimethyl thiazolyl diphenyl tetrazolium salt  
NFκB ……………….. Nuclear factor κB 
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NSLC ………………… Non-small lung carcinoma  
PBS ………………….. Phosphate buffered saline  
PDGF ………………... Platelet-derived growth factor  
PI ………………….…. Propidium iodide  
PI3K ………….………. Phosphotidyl-inositol-3-OH kinase  
PMSF ………………… Phenylmethanesulfonylfluoride  
PVDF ……..….………. Polyvinylidene fluoride  
Rb ……………...…….. Retinoblastoma protein  
RCC ………..….….….. Renal cell carcinoma  
ROS ……………….…. Reactive oxygen species 
RTK ………………….. Tyrosine kinase receptor 
SDS-PAGE ……….…. Sodium dodecyl sulfate polyacrylamide gel electrophoresis  
TAM ………………….. Tumor-associated macrophage  
TBST …..……….……. Tris-buffered saline with Tween  
TFβ ………………….. Tumor growth factor β  
TNFα ……..........…….Tumor necrosis factor α  
VEGF ……….....……... Vascular endothelial growth factor  
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